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ABSTRACT OF DISSERATION 
 
 
 
 
IN VITRO AND IN VIVO CHARACTERIZATION OF A TRANS EXCISION-SPLICING 
RIBOZYME 
 
Group I introns are catalytic RNAs with the ability to splice out of RNA 
transcripts, often without the aid of proteins. These self-splicing introns have been 
reengineered to create ribozymes with the ability to catalyze reactions. One such 
ribozyme, derived from a Pneumocystis carinii group I intron, has been engineered 
to sequence specifically remove a targeted segment from within an RNA substrate, 
which is called the trans excision-splicing reaction. 
The two catalytic steps of the trans excision-splicing reaction occur at 
positions on the substrate known as the 5’ and 3’ splice sites. Strict sequence 
requirements at these sites could potentially limit the target choices for the trans 
excision-splicing ribozyme, so the sixteen possible base pair combinations at the 5’ 
splice site and the four possible nucleotides at the 3’ splice site were tested for 
reactivity. All base pair combinations at the 5’ splice site allow the first reaction step 
(5’ hydrolysis) to occur and several combinations allow the second step to occur, 
resulting in trans excision-splicing product formation. Moreover, we found that non-
Watson-Crick base pairs are important for 5’ splice site recognition and prevent 
product degradation via hydrolysis at other sequence positions. The sequence 
requirement at the 3’ splice site is absolute, as guanosine alone produced complete 
product.  
To date, the experiments with the trans excision-splicing ribozyme have been 
conducted in vitro. The further development of this ribozyme as a biochemical tool 
and as a potential therapeutic agent requires in vivo reactivity. Thus, a prokaryotic 
system was designed and tested to assess the catalytic potential of the trans 
excision-splicing ribozyme. We show that the ribozyme successfully excised a 
single, targeted nucleotide from a mutated green fluorescent protein transcript in 
Escherichia coli. On average, 12% correction was observed as measured by 
fluorescence and approximately 1.2% correction was confirmed through sequence 
analysis of isolated transcripts. 
We have used these studies to further characterize trans excision-splicing 
ribozymes in vitro and to pave the way for future development of this ribozyme 
 
reaction in vivo. These results increase our understanding of this ribozyme and 
advance this reaction as a biochemical tool with potential therapeutic applications. 
 
Keywords:  Group I intron; ribozyme; trans excision-splicing; splice site 
sequence requirements; in vivo targeted nucleotide excision 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dana Ann Baum 
 
August 2, 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IN VITRO AND IN VIVO CHARACTERIZATION OF A TRANS EXCISION-SPLICING 
RIBOZYME 
 
 
 
By 
Dana Ann Baum 
 
 
 
 
 
 
 
 
 
 
 
 
Stephen M. Testa, Ph.D. 
Director of Dissertation 
 
Mark Meier, Ph.D. 
Director of Graduate Studies 
 
August 2, 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RULES FOR THE USE OF DISSERATIONS 
 
 
Unpublished dissertations submitted for the Doctor’s degree and deposited in the 
University of Kentucky Library are as a rule open for inspection, but are to be used 
only with due regard to the rights of the authors. Bibliographical references may be 
noted, but quotations or summaries of parts may be published only with the 
permission of the author, and with the usual scholarly acknowledgements. 
 
 
Extensive copying or publication of the dissertation in whole or in part also requires 
the consent of the Dean of the Graduate School of the University of Kentucky.
 
 
 
 
 
 
 
 
 
 
 
DISSERATION 
 
 
 
 
 
 
 
 
Dana Ann Baum 
 
 
 
 
 
 
 
 
 
The Graduate School 
 
University of Kentucky 
 
2005
 
 
 
 
 
 
 
IN VITRO AND IN VIVO CHARACTERIZATION OF A TRANS EXCISION-SPLICING 
RIBOZYME 
 
 
 
 
 
 
 
DISSERTATION 
 
 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of Doctor of Philosophy in the  
College of Arts and Sciences 
at the University of Kentucky 
 
 
 
 
By 
Dana Ann Baum 
 
Lexington, KY 
 
Director:  Dr. Stephen M. Testa, Professor of Chemistry 
 
Lexington, Kentucky 
 
2005 
 
Copyright © Dana Ann Baum 2005 
 
ACKNOWLEDGEMENTS 
 
I would not have been able to complete the work presented in this dissertation 
without the support and guidance of many people. First, I want to thank my research 
advisor, Dr. Stephen Testa. He entrusted me with a research project that was 
challenging, high risk, and important to future projects in the lab and I am grateful for 
the opportunity to make that project a success. He gave me the room necessary to 
figure out the details and to work through the problems I encountered along the way, 
but he also pushed me when he felt it was necessary. I learned so much along the 
way and I gained valuable experience in manuscript writing, grant writing, and other 
tasks involved in running a lab. I will take these experiences with me as I go off to 
pursue my goal of becoming a professor at a research university. Thank you, Steve, 
for introducing me to a research area that is challenging and exciting. I appreciate 
your advice and the lively discussions on numerous topics, especially hockey. I have 
truly enjoyed my time in your lab and even when times were tough, I loved the work I 
was doing. 
My time in Dr. Testa’s lab was made even more enjoyable because of my lab 
mates, both past and present. Dr. Michael Bell went out of his way to make me feel 
welcome and I learned so much from him during our morning coffee breaks. He is 
one of the most unique individuals I have ever met. Dr. Rashada Alexander has 
been a wonderful friend and always offered support and a sympathetic ear when I 
needed to vent. Dr. Ashley Johnson was also a source of support during my 
graduate school career. I also want to thank “the guys” in the lab. I had the pleasure 
of working with Joy Sinha on the splice site project presented in this dissertation. I’m 
still amazed at where that project started and how much more interesting it ended up 
being. I want to thank Patrick Dotson for his insights on GFP and the discussions 
about the trials and tribulations of working in vivo. I know the in vivo project is in 
good hands. Nick Tzouanakis was a lively addition to the lab and always had a way 
of making things interesting. Dustin Lafferty was a great help to me when I was 
completing the in vivo project and I appreciate his hard work and friendship. 
 iii 
  
I would also like to thank the members of my committee:  Dr. Leonidas 
Bachas, Dr. Martha Peterson, Dr. Brian Rymond, and Dr. John Selegue. I appreciate 
their time spent serving on my committee. I am indebted to many members of the 
Chemistry Department. I especially want to thank Joyce Cambron, Geri Gerke, 
Jamie Torp, and June Smith in the Main Office for their help with various tasks. My 
thanks also goes out to Yuvonne Queen in the Graduate Program Office for her help 
in getting the appropriate paperwork filled out and submitted. I also appreciate the 
interactions I have had with various faculty members during my time at UK. I truly 
enjoyed my time here.  
I would not be where I am today without the love and support of my family. 
First and foremost, I would like to thank my mom, Trish Baum. Mom, I know it was 
hard for you to let me go when I decided to move to Kentucky to go to grad school, 
but you stood by me as I pursued my goals. Thank you so much for everything you 
have done for me. I also want to thank my sister, Dawn, who is not only my sister, 
but also my best friend. Dawn, I know it wasn’t always easy having me as a sister, 
but I am so proud of you and of the person you are. You have been a great source 
of strength for me and have been so supportive and encouraging, especially when I 
was stressed. I would like to thank my dad, Richard Baum, for his support of my 
decision to go to graduate school. I also want to thank my grandma, Mary Williams, 
for the notes and the phone calls to see how I was doing, even when she wasn’t 
feeling the greatest. I am indebted to my aunt and uncle, Sandy and “Uncle” Dan 
Trobaugh, for letting me visit them for much needed vacations. My thanks also goes 
out to my neighbor back home, the Honorable Joseph Koval. While many people 
know him as Judge, to me he’s just Joe. Thank you so much for everything you have 
done for me and my family. 
Dealing with the stresses of graduate school has been easier thanks to my 
wonderful friends. I especially want to thank Andrea Belko for her friendship. She 
was one of the first people I met who understood why I liked science so much 
because of her love of science and her desire to go to medical school. It has been 
so nice to have someone to talk to who understands how a research lab works. My 
thanks also goes out to Judith McCart for her ever optimistic outlook on life. To the 
 iv 
  
other friends I have made while growing up in Illinois and during my time at 
Washington University in St. Louis, Missouri, thank you for the experiences you have 
brought into my life. Even if we have lost touch, you are still on my mind and in my 
heart. 
Last, but certainly not least, I want to thank God for all his gifts. I feel truly 
blessed by the talents he has given me and by the people he has brought into my 
life. Whenever I felt overwhelmed, faith and prayer saw me through. I would not be 
writing this work today if it was not for Him and for that I am so thankful. 
 v 
  
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ..........................................................................................iii 
TABLE OF CONTENTS.............................................................................................vi 
LIST OF TABLES.......................................................................................................ix 
LIST OF FIGURES .................................................................................................... x 
CHAPTER 1 – INTRODUCTION ............................................................................... 1 
Investigation of the Sequence Requirements for the TES Ribozyme  
at the 5’ and 3’ Splice Sites ............................................................................. 1 
Investigation of the Ability of the TES Ribozyme to Excise a Single,  
Targeted Nucleotide from an mRNA In Vivo ................................................... 2 
CHAPTER 2 – BACKGROUND ................................................................................. 4 
Nucleic Acids................................................................................................... 4 
Deoxyribonucleic acid (DNA)................................................................ 4 
Ribonucleic acid (RNA) ........................................................................ 5 
Catalytic RNA.................................................................................................. 6 
Self-splicing group I intron .................................................................... 7 
Trans excision-splicing reaction ........................................................... 8 
Green Fluorescent Protein .............................................................................. 9 
Methodologies............................................................................................... 10 
Gel electrophoresis............................................................................. 10 
Autoradiography ................................................................................. 11 
Sub-cloning ........................................................................................ 11 
PCR and RT-PCR .............................................................................. 12 
Site-directed mutagenesis .................................................................. 13 
Fluorescence spectroscopy................................................................ 14 
CHAPTER 3 - DETERMINATION OF THE SPLICE SITE SEQUENCE 
REQUIREMENTS FOR THE TRANS EXCISION-SPLICING RIBOZYME............... 30 
 vi 
  
Proposed Project........................................................................................... 30 
Materials and Methods.................................................................................. 31 
Nucleic acid synthesis and preparation .............................................. 31 
Radiolabeling RNA oligonucleotides................................................... 31 
Ribozyme preparation ........................................................................ 32 
Trans excision-splicing reactions........................................................ 33 
Competition assays ............................................................................ 34 
Results .......................................................................................................... 34 
Molecular recognition at the 5’ splice site ........................................... 34 
Source of cryptic products .................................................................. 37 
Molecular recognition at the 3’ splice site ........................................... 39 
Discussion..................................................................................................... 40 
Molecular recognition at the 5’ splice site ........................................... 40 
Relative effectiveness of each base in each position of the  
5’ splice site........................................................................................ 43 
Molecular recognition at the 3’ splice site ........................................... 44 
P9.0 and P10 are not required for TES reactions............................... 44 
A mechanism for ribozyme-mediated TES product degradation ........ 46 
Non-Watson-Crick base pairs at the 5’ splice site can help  
determine the binding register of reaction substrates......................... 46 
ωG can help determine the binding register of reaction substrates.... 47 
Implications ........................................................................................ 48 
CHAPTER 4 - IN VIVO EXCISION OF A SINGLE TARGETED NUCLEOTIDE FROM 
AN RNA TRANSCRIPT BY A TRANS EXCISION-SPLICING RIBOZYME.............. 66 
Proposed Project........................................................................................... 66 
Materials and Methods.................................................................................. 67 
Oligonucleotide synthesis and preparation......................................... 67 
Plasmid construction .......................................................................... 67 
Preparing competent JM109(DE3) ..................................................... 71 
Transformation of competent JM109(DE3)......................................... 71 
In vivo TES reactions.......................................................................... 72 
 vii 
  
Analysis .............................................................................................. 72 
Total RNA isolation............................................................................. 73 
RT-PCR reactions .............................................................................. 73 
Assay for corrected transcripts ........................................................... 74 
System Design .............................................................................................. 75 
Design of the in vivo test system ........................................................ 75 
Experimental design for the assay for corrected transcripts ............... 77 
Results .......................................................................................................... 78 
The expected product form of GFP is fluorescent .............................. 78 
The TES ribozyme is active in vivo..................................................... 79 
The targeted guanosine is removed from the corrected transcripts.... 80 
Discussion..................................................................................................... 81 
Comparison to in vitro TES results ..................................................... 81 
Comparison to trans-splicing .............................................................. 83 
Comparison to SMaRT....................................................................... 84 
Comparison to RNA cleavage methods.............................................. 85 
Issues ................................................................................................. 86 
Implications ................................................................................................... 87 
CHAPTER 5 - CONCLUSIONS ............................................................................... 98 
The Sequence Requirements for the TES Ribozyme at the 5’ and 3’  
Splice Sites ................................................................................................... 98 
The TES Ribozyme Can Excise a Single, Targeted Nucleotide from  
an mRNA In Vivo........................................................................................... 99 
References ............................................................................................................ 101 
Vita......................................................................................................................... 113 
 viii 
  
LIST OF TABLES
 
Table 3.1:  Relative Effectiveness of Each Base in Each Position of the 5’ Splice Site 
in TES Reactions ..................................................................................................... 50 
 ix 
  
LIST OF FIGURES 
 
Figure 2.1.  Deoxyribonucleotide ........................................................................... 15 
Figure 2.2.  The Nitrogenous Bases in DNA.......................................................... 16 
Figure 2.3.   Structure of a DNA Strand.................................................................. 17 
Figure 2.4.  Double Helix Structure of DNA ........................................................... 18 
Figure 2.5.  Watson-Crick Base Pairing in DNA .................................................... 19 
Figure 2.6.     Central Dogma of Molecular Biology .................................................. 20 
Figure 2.7.     Ribonucleotide.................................................................................... 21 
Figure 2.8.     Uracil .................................................................................................. 22 
Figure 2.9.     Examples of RNA Secondary Structure.............................................. 23 
Figure 2.10.   Self-Splicing of Group I and Group II Introns...................................... 24 
Figure 2.11.   Predicted Secondary Structure of the Pneumocystis carinii  
                      Self-Splicing Group I Intron ................................................................ 25 
Figure 2.12.   Self-Splicing Reaction of a Group I Intron .......................................... 26 
Figure 2.13.   Predicted Secondary Structure of the Pneumocystis carinii  
                      Ribozyme ........................................................................................... 28 
Figure 2.14.   Trans Excision-Splicing Reaction ....................................................... 29 
Figure 3.1.     The u-G Wobble Pair.......................................................................... 51 
Figure 3.2.     Conserved Splice Site Sequences ..................................................... 52 
Figure 3.3.     5’ Splice Site Test System.................................................................. 53 
Figure 3.4.     Results for the 5’ Splice Site During 1 Hour Reaction Times.............. 54 
Figure 3.5.     Time Studies Investigating the Formation of Cryptic Products ........... 56 
Figure 3.6.     Results for the 5’ Splice Site During 15 Minute Reaction Times......... 58 
Figure 3.7.     Results for the 5’ Splice Site Using 3’ End Labeled Substrates.......... 60 
Figure 3.8.     Time Studies to Identify the Source of the Cryptic Products............... 61 
Figure 3.9.     Competition Studies Investigating Product Dissociation and  
                      Rebinding ........................................................................................... 62 
Figure 3.10.   Results for the 3’ Splice Site for 1 Hour Reaction Times .................... 63 
Figure 3.11.   Results for Reactions Where no P10 Formation Is Possible .............. 65 
Figure 4.1.     Design of the GFP Target System...................................................... 89 
Figure 4.2.     The Trans Excision-Splicing Ribozyme with a T7 Terminator  
                      Sequence ........................................................................................... 90 
Figure 4.3.     Plasmid Construction.......................................................................... 91 
Figure 4.4.     GFP Ribozyme Base Pairing With Its Target...................................... 93 
Figure 4.5.     Schematic of the Assay to Selectively Isolate Corrected  
 Transcripts.......................................................................................... 94 
Figure 4.6.     Fluorescence Levels for Normal, Mutant and Expected Product  
                      Forms of GFP..................................................................................... 95 
Figure 4.7.     TES Correction of Mutant GFP........................................................... 96 
Figure 4.8.     Sequencing Results for Non-Fluorescent and Fluorescent Colonies . 97 
 
 x 
  
CHAPTER 1 – INTRODUCTION 
 
Ribonucleic acid, or RNA, is a biomolecule with an interesting history. It plays 
a pivotal role in the central dogma of molecular biology, yet it was initially thought to 
be a relatively passive molecule. The discovery of RNA molecules with the ability to 
catalyze chemical reactions in the early 1980’s (1, 2) changed this view of RNA and 
led to the development of new areas of research. These areas of research have 
focused on characterizing these catalytic RNAs, or ribozymes, and utilizing their 
properties to catalyze new reactions (3-30). 
One such catalytic RNA, a group I intron-derived ribozyme from the 
opportunistic pathogen Pneumocystic carinii, has been the focus of ongoing work in 
the Testa lab (11, 22, 30-34). We have previously reported that this ribozyme can 
catalyze a reaction called the trans excision-splicing (TES) reaction (22). In this 
reaction, the ribozyme binds an RNA substrate and excises from that substrate an 
internal segment. This reaction has potential use as a biochemical tool for the 
sequence specific modification of RNA molecules. This ribozyme also has potential 
therapeutic applications in that it could be used to remove mutations (at the RNA 
level) that are implicated in a host of genetic diseases. The trans excision-splicing 
reaction also serves as a unique model system for studying the structure and 
function of group I introns. The research presented in this work further characterizes 
the TES ribozyme in vitro by elucidating molecular recognition components of the 5’ 
and 3’ splice sites (33). This ribozyme was also characterized by demonstrating, for 
the first time, the in vivo catalytic abilities of the TES ribozyme in the bacterium 
Escherichia coli (30). 
Investigation of the Sequence Requirements for the TES Ribozyme at the 5’ 
and 3’ Splice Sites 
TES ribozymes recognize their targets initially through base pairing. These 
base pairing interactions also help define the sites of catalysis, which are called 
splice sites. In work with the P. carinii intron (11, 31) and the ribozyme derived from 
this intron (22, 32), the highly conserved nucleotide sequences that define the 5’ and 
3’ splice sites in group I introns were maintained. Specific sequence requirements at 
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these critical positions would limit the sequences that could be targeted by TES 
ribozymes, so in conjunction with another member of the Testa lab, Joy Sinha, we 
investigated all possible sequences for those that allowed catalytic activity at these 
splice sites (33). These studies were also undertaken to gain insight into the 
molecular recognition of the splice sites by this ribozyme. 
The results show that the sequence requirement at the 5’ splice site is not 
stringent, however, certain sequences should be avoided to prevent degradation of 
the subsequent TES products (33). This lax sequence specificity indicates the 
molecular recognition of the 5’ splice site is dependent on structure, and not 
sequence (i.e., base pairing). Conversely, the sequence requirement at the 3’ splice 
site is absolute, with only guanosine allowing for TES product formation (33). These 
results allow us to establish guidelines for new TES target systems. The results also 
indicate that changing the 3’ splice site sequence to nucleotides other than 
guanosine will require an as yet unknown modification of the ribozyme. 
Investigation of the Ability of the TES Ribozyme to Excise a Single, Targeted 
Nucleotide from an mRNA In Vivo 
While TES ribozymes are potentially useful biochemical tools for the in vitro 
modification of RNA, their applicability could be greatly expanded by demonstrated 
in vivo reactivity. These ribozymes could be used as tools for the sequence specific 
modification of RNA transcripts in a cell. As a therapeutic agent, TES ribozymes 
could be used to target genetic mutations at the RNA level that are known to lead to 
disease. The benefit of this type of approach to treatment is that the transcript used 
for protein production is being fixed. This repair reduces the amount of mutant 
transcript, while increasing the amount of functional transcript. This differs from the 
approach of many recent RNA-based therapeutics, which simply destroy the mutant 
transcripts (18, 24, 35-40). To this end, a test system was designed to assess the 
ability of a TES ribozyme to excise a single, targeted nucleotide from an mRNA 
transcript in E. coli (30).  
This testing showed that the P. carinii ribozyme is able to catalyze the trans 
excision-splicing reaction in a cellular environment. The ribozyme was successfully 
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reengineered to target and remove a single-base insertion mutation engineered into 
a green fluorescent protein gene. On average, 12% correction was observed as 
measured by fluorescence, and approximately 1.2% correction was confirmed 
through sequence analysis (30). The greatest amount of TES reactivity (as 
measured by the largest increase in restored fluorescence) was seen in tests 
involving a ribozyme with increased base pairing interactions with the substrate. This 
ribozyme-mediated repair of the transcript occurs with no observed detrimental 
effects on the cells. Corrected transcripts were selectively isolated and sequenced to 
confirm the removal of the targeted nucleotide (30). These results represent the first 
example of a catalytic RNA specifically excising a targeted nucleotide from within an 
RNA substrate in vivo. 
The work presented here helps further characterize the trans excision-splicing 
ribozyme in vitro (33) and in vivo (30). The results from the splice site study establish 
a framework for designing new target systems, while the demonstrated activity of the 
TES ribozyme in a prokaryotic system lays the ground work for further development 
of TES ribozymes in vivo, including tests of TES ribozyme reactivity in mammalian 
systems. These studies demonstrate the usefulness of the TES reaction as a way to 
study the structure and function of group I intron-derived ribozymes. These results 
also play a vital role in expanding the potential uses of this novel ribozyme, including 
those applications with potential therapeutic value. 
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CHAPTER 2 – BACKGROUND 
 
Nucleic Acids 
Nucleic acids are polymers of nucleotides, with each nucleotide consisting of 
a phosphate group, a five-carbon sugar and a nitrogenous base. There are two 
forms of nucleic acids:  deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). 
Deoxyribonucleic acid (DNA) 
DNA is the genetic storage material in a cell, and it gets its name from the 
deoxyribose sugar in its nucleotides (Figure 2.1). There are four different nucleotides 
that make up DNA. The identity of the nitrogenous base attached to the sugar is 
what makes each nucleotide distinct. There are 4 nitrogenous bases (or 
nucleobases) found in DNA (Figure 2.2): adenine (A), guanine (G), cytosine (C), and 
thymine (T). The nucleotides are commonly referred to by the single letter 
abbreviations of the attached nucleobases, shown in parentheses. Adenine and 
guanine are purines, while cytosine and thymine are pyrimidines. 
In nucleic acids, the nucleotides are polymerized. The connection is made 
between the sugars and the phosphate groups of adjacent deoxyribonucleotides. 
Specifically, the linkage is a phosphodiester bond between the 3’ hydroxyl group of 
one nucleotide and the 5’ phosphate group of the next nucleotide (Figure 2.3). This 
series of connections is called the sugar-phosphate backbone or the phosphodiester 
backbone. The first and last nucleotides of the polymer (or strand) have available 5’ 
(first nucleotide) or 3’ (last nucleotide) functional groups. Thus, a strand has 
directionality, and the order of the nucleotides is read from either the 5’ end to the 3’ 
end or vice versa. This directionality is denoted when representing a DNA strand by 
the single letter abbreviations of the nucleobases. As an example, the strand 
5’GCAT3’ is different from the strand 3’GCAT5’ because the nucleotides are being 
read from opposite directions. 
In DNA, two strands come together to form a double helix. In the double helix, 
the nitrogenous bases of the opposing strands are oriented into the center of the 
helix and form base pairs through hydrogen bonding. These base pairing 
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interactions hold the strands together and look like the rungs of a ladder. The bases 
also stack upon each other, which lends further stability to the structure (41). The 
sugar-phosphate backbones twist around the central axis in a right-handed direction 
(Figure 2.4). The base pairing interactions found in DNA are the Watson-Crick base 
pairs. They are stable interactions and are specific, with adenine pairing with 
thymine via two hydrogen bonds and guanine pairing with cytosine via three 
hydrogen bonds (Figure 2.5). The Watson-Crick base pairs are isosteric, meaning 
exchanging one pair (A-T) with another pair (G-C) does not significantly change the 
structure of the sugar-phosphate backbones (42). This allows for the constancy of 
the double helical structure, regardless of the order of the base pairs. The 
backbones of each strand run in the opposite directions, so one strand runs in the 5’-
to-3’ direction, while its complement runs in the antiparallel direction of 3’-to-5’. DNA 
is stable because of this double helix structure. This stability is dependent on the 
base pairing interactions, as well as the stacking of the base pairs. 
Ribonucleic acid (RNA) 
In the central dogma of molecular biology (Figure 2.6), RNA acts as the 
intermediate between the genetic material (DNA) and the functional product 
(protein). Research shows, however, that RNA is much more than a passive 
intermediate (1, 2, 43, 44). RNA, like DNA, is a polymer of nucleotides. There are 
two key differences between RNA and DNA. First, the sugar in RNA is a ribose (with 
a hydroxyl group on the 2’ carbon of the sugar) rather than a deoxyribose (Figure 
2.7), thus the name ribonucleic acid. This 2’ hydroxyl group gives RNA an additional 
functional group that is available for structural interactions and chemical reactions. 
Also, the nitrogenous base thymine, which is found in DNA, is replaced by uracil (U). 
Uracil differs from thymine by the replacement of a methyl group with a hydrogen 
atom (Figure 2.8). 
Unlike DNA, RNA is synthesized in a single stranded form. It is capable, 
however, of forming secondary structure through intramolecular or intermolecular 
base pairing interactions. Thus, RNA can form double stranded regions, similar to 
the DNA double helix structure, as well as other structures that leave nucleobases 
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available for interactions (Figure 2.9). These secondary structures, as well as tertiary 
structures involving long range interactions, allow RNA transcripts to form 3-
dimentional structures, some with potential catalytic structures.  
Catalytic RNA  
In the early 1980’s, the view of the role of RNA in the cell changed with the 
discover of catalytic RNAs (1, 2). The first catalytic RNA discovered was a self-
splicing group I intron from the ciliate Tetrahymena thermophila (1). This finding was 
soon followed by the discovery that the RNA component of RNase P (which is 
responsible for the processing of tRNA molecules) is the catalytic subunit of the 
complex (2). Introns are intervening sequences found in RNA transcripts that make 
functional sequences, called exons, discontinuous. Introns are removed from RNA 
transcripts via splicing. A group I intron is capable of catalyzing its own excision from 
an RNA transcription (1). Group I introns are widespread in nature and they have 
been found in mRNA, tRNA, and rRNA transcripts from many organisms, including 
algae, fungi, and other unicellular eukaryotic organisms (45). They share a similar 
secondary structure and a common splicing mechanism. Another type of catalytic 
intron, the self-splicing group II intron, was later discovered (46). Group I and group 
II introns differ in their secondary structures and in their splicing mechanisms (Figure 
2.10). Thus, catalytic RNA molecules can utilize different mechanisms to achieve the 
same result: excision of the intron and ligation of the flanking exons. 
Since the initial discoveries of these large catalytic RNAs, other naturally 
occurring catalytic RNAs have been found, including the small cleaving ribozymes. 
These ribozymes include the hairpin, hammerhead, Hepatitis Delta Virus (HDV), and 
Neurospora Varkud Satellite (VS) ribozymes (18, 37, 43, 47, 48). These small 
ribozymes are associated with various satellite and virus RNAs (47, 49), and they 
cleave the phosphodiester backbone of an RNA molecule to produce 2’,3’ cyclic 
phosphates. Group I introns, group II introns, and RNase P cleave the 
phosphodiester backbone in a different manner to produce 3’ OH groups. The small 
cleaving ribozymes are of great interest for the sequence specific cleavage of RNA 
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targets because of their small size and ease of adaptability, as they recognize their 
targets primarily through simple base pairing.  
Self-splicing group I intron 
The trans excision-splicing reaction studied in this work is based on the self-
splicing reaction of group I introns. In this reaction, the intron folds into its catalytic 
form through extensive base pairing and tertiary interactions. In this folding pathway, 
the intron also base pairs with its 5’ and 3’ exons, which will ultimately be ligated 
together (Figure 2.11), via three important base pairing interactions. The intron 
sequences responsible for these key targeting interactions are termed recognition 
elements (abbreviated as RE) (22). Recognition element 1 (RE1) base pairs with the 
3’ end of the 5’ exon (shown in blue; Figures 2.11 and 2.12) to form a base paired 
helix called P1. The 5’ end of the 3’ exon (shown in red; Figures 2.11 and 2.12) is 
recognized by RE3 and forms the P10 helix. Recognition elements 1 and 3 are side 
by side (and in some cases overlapping) in group I introns and together compose 
the internal guide sequence or IGS (6, 31, 50). A third important contact is made 
between two segments of the intron itself. RE2 (which is near the catalytic core of 
the intron) base pairs with sequences near the 3’ end of the intron (near the 3’ splice 
site) to form the P9.0 helix (Figures 2.11 and 2.12). These interactions allow for 
recognition of the correct splice sites and align the exons for the splicing event.  
The first catalytic step of self-splicing is 5’ cleavage (Figure 2.12). An 
exogenous guanosine nucleotide binds a particular site in the intron known as the 
guanosine binding site [also known as the G-binding site or the GBS, shown in the 
gray oval in Figure 2.11] (51, 52). The 3’ hydroxyl of this guanosine monophosphate 
serves as a nucleophile and attacks the phosphodiester backbone of the 5’ exon at 
the 5’ splice site. The backbone is cleaved, resulting in a 3’ hydroxyl on the terminal 
uridine nucleotide at the splice site (the last base of the 5’ exon). The guanosine 
nucleophile is attached to the end of the intron [Figure 2.12] (1, 53, 54). The second 
reaction step is exon ligation, in which the 3’ hydroxyl of the terminal uridine of the 5’ 
exon attacks the phosphodiester backbone at the 3’ splice site [Figure 2.12] (55, 56). 
This nucleophilic attack ligates the exons together and releases the intron. The 
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excised intron still maintains catalytic activity and goes on to circularize via an 
intramolecular attack (1, 57, 58).  
The group I intron is a single-turnover catalyst in terms of the self-splicing 
reaction. The intron can only self-splice out of the transcript once. Removing the 
exon sequences (which are the substrates in the self-splicing reaction) from the 
intron produces a ribozyme, or an RNA enzyme. These ribozymes can now function 
in a multiple-turnover fashion and catalyze reactions using exogenous substrates 
(Figure 2.13). These ribozymes have been used to characterize the steps and the 
sequence requirements of the self-splicing reaction (16, 59-76). They are also being 
reengineered to perform new catalytic reactions (3, 4, 7, 22, 34, 56, 77-79).  
Trans excision-splicing reaction 
The trans excision-splicing (TES) reaction was developed by the Testa lab 
using a ribozyme (~330 nucleotides in length) derived from a group I intron in an 
rRNA gene from the opportunistic pathogen Pneumocystis carinii (11, 80, 81). This 
ribozyme can catalyze the excision of a targeted sequence from within an RNA 
substrate (22). First, the ribozyme folds into its catalytic form (Figure 2.13). The 
three molecular recognition elements used by the self-splicing intron (described 
above) are utilized by the TES ribozyme to identify its target. RE1 base pairs with 
the 5’ end of the substrate, forming the P1 helix (Figure 2.14). RE2 base pairs with 
the segment targeted for excision (when longer than a single nucleotide) to form the 
P9.0 helix, while RE3 base pairs with the 3’ end of the substrate to form the P10 
helix (Figure 2.14). Thus, the ribozyme recognizes its target through simple base 
pairing. Not all of these base pairing interactions are required for reactivity, as test 
systems that do not allow P9.0 formation still produce appreciable amounts of TES 
product (22, 33). 
After the ribozyme has bound an RNA substrate containing the sequence 
targeted for excision, the first reaction step occurs (Figure 2.14). In this 5’ cleavage 
reaction, a hydroxyl (presumably from a water molecule bound to the ribozyme) 
attacks the phosphodiester backbone of the substrate specifically at the 5’ splice 
site, generating 5’ and 3’ exon intermediates (22). This differs from the first step of 
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the self-splicing reaction, which utilizes guanosine as the nucleophile. The result, 
however, is the same, as the phosphodiester backbone of the substrate is cleaved to 
produce a 3’ hydroxyl group on the terminal nucleotide of the 5’ exon (a uridine). In 
the second reaction step (exon ligation), the 3’ hydroxyl on the terminal nucleotide of 
the 5’ exon attacks a specific base within the 3’ exon intermediate, simultaneously 
ligating the exon intermediates and excising the targeted internal segment. This 
internal segment can vary in size, as sequences from 1 to 28 nucleotides have been 
successfully excised (22). The ribozyme recognizes its target primarily through base 
pairing, so changing the sequence of the recognition elements of the ribozyme can 
direct the ribozyme to different substrates (22), while increasing the length of these 
interactions can improve reactivity (32). 
Green Fluorescent Protein 
The studies investigating the ability of the P. carinii ribozyme to catalyze the 
TES reaction in vivo utilize a green fluorescent protein gene as the target (30). 
Green fluorescent protein (GFP) originates from the jellyfish Aequorea victoria (82). 
Excitation of the protein with blue or UV light results in the emission of fluorescence 
in the green region of the visible spectrum. The protein has a highly stable structure, 
known as a β-can structure (83, 84), which is resistant to a wide variety of 
denaturing conditions (85). Fluorescence is dependent on the formation of the 
chromophore by cyclization and oxidation of three particular amino acids (Serine65-
Tyrosine66-Glycine67) in the core of the protein (82-86). The chromophore formation 
for GFP is autocatalytic (87) and does not require species-specific cofactors, as GFP 
has been successfully expressed in a wide range of hosts and cell lines (85, 88-91). 
The highly stable structure of the protein and the autocatalytic formation of the 
chromophore (seeming to only require molecular oxygen), make GFP an attractive 
tool for labeling molecules for various studies in vivo.  
The wild type form of GFP has two excitation peaks:  a major peak at 395 nm 
and a minor peak at 475 nm. These excitations correspond with emissions at 508 
nm and 503 nm, respectively (92). Analyses of randomly mutated forms of the gene 
have led to the engineering of GFP proteins with altered spectral properties to 
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improve the usability of these proteins in biological applications (82, 93). The form of 
GFP utilized in this work was developed by Quantum (distributed by QBioGene; 
Carlsbad, CA) and is a red-shifted version of GFP (rsGFP). In this form of GFP, 
Serine65 has been mutated to Cysteine65. This mutation changes the excitation 
spectrum from a double peak (described above) to a single peak at ~473 nm (94). 
This change in the excitation maximum is desirable, because this and other red-
shifted variants exhibit greater photostability than wild type GFP (88, 94). The 
emission peak for the form of GFP used in these studies is at ~509 nm, essentially 
the same as an emission peak for the wild type form of GFP (94). 
Methodologies 
Gel electrophoresis 
Gel electrophoresis is a method for separating biomolecules, generally by 
mass (95). While gel electrophoresis is also utilized for separating proteins, the 
descriptions outlined here will focus on the separation of nucleic acids (DNA or 
RNA). There are two types of gels used for these separations:  agarose and 
polyacrylamide. Agarose, which is derived from seaweed, is best suited for 
separating large segments of nucleic acids, from as small as 50 base pairs to 
several thousand base pairs in length (95). The percentage of agarose used in the 
gel matrix determines the size of the molecules that can be effectively separated. 
Larger, unstructured molecules will be impeded in their migration through the matrix, 
while smaller or structured molecules will migrate faster. Agarose gels are used in 
the work presented here to estimate the size of large DNA or RNA molecules 
(relative to controls) and to separate and purify large pieces of DNA for applications 
such as plasmid construction. 
Polyacrylamide gels are used for higher resolution of molecules and can allow 
for the separation of molecules differing by a single nucleotide (95). Polyacrylamide 
gels are composed of polymerized acrylamide crosslinked with bis-acrylamide to 
form a polyacrylamide lattice. The percentage of acrylamide and the ratio of 
acrylamide to bis-acrylamide determine the size range of molecules that can be 
effectively separated. Polyacrylamide gels can be native (non-denaturing) or 
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denaturing. Native polyacrylamide gels maintain the structure of the molecules being 
separated, allowing for different forms of the same molecule to be separated. 
Denaturing gels contain a denaturant, such as urea, to disrupt any self-structure (for 
example via base pairing) and allow for the separation of molecules based on size 
(or mass) alone. Native polyacrylamide gels are used in this work to purify 
radiolabeled substrates for use in in vitro studies. Denaturing polyacrylamide gels 
are used to separate reaction substrates, products, and intermediates after 
conducting in vitro reactions. The presence of the denaturant (urea) promotes the 
dissociation of the product from the ribozyme. 
Autoradiography 
Autoradiography is a method used to visualize biomolecules based on the 
decay of a radioactive label (96). In this work, radioactive phosphorus (32P) is used 
to label DNA or RNA oligonucleotides on either the 5’ end or the 3’ end of the 
molecule. For labeling the 5’ end of an oligonucleotide, the reaction involves the 
transfer of the radioactive phosphorus from ATP to the desired molecule by a 
kinase. To label the 3’ end of a molecule, a cytidine monophosphate nucleotide that 
has been labeled with a radioactive phosphate (*pCp) is ligated to the end of the 
molecule by an RNA ligase (97). These labeled molecules are purified by 
polyacrylamide gel electrophoresis (PAGE) and are then used as substrates in in 
vitro reactions. After a reaction is complete, the resulting products are separated on 
polyacrylamide gels. The gels are then dried under vacuum to trap the molecules in 
place, and the dried gels are exposed to a PhosphorImager screen, which detects 
the energy from the decay of the radioactive phosphorus. After an overnight 
exposure, the screen is scanned using a PhosphorImager. The resultant gel image 
allows us to determine the size of products of the reaction, based on the migration of 
the bands relative to size controls. The intensities of the bands are quantified, and 
these intensities allow us to determine the extent of a reaction. 
Sub-cloning 
In sub-cloning, a DNA fragment of interest is ligated into a cloning vector, also 
known as a plasmid. Plasmids are self-replicating, double-stranded, circular DNA 
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molecules (96). For molecular cloning purposes, a plasmid will typically contain an 
origin of replication specific for the organism the plasmid will be introduced into; a 
selectable marker, such as an antibiotic resistance gene, to allow for selection of 
cells containing the plasmid; and a multiple cloning site to allow for the insertion of 
the sequence of interest. This multiple cloning site consists of sequences that can be 
cleaved by restriction enzymes. Restriction enzymes are bacterial endonucleases, or 
enzymes that cut DNA molecules internally at specific base pair sequences (96). 
Digesting DNA molecules with restriction enzymes produces DNA fragments with 
specific, known ends. This allows for the joining of DNA molecules in a sequence-
specific manner. The cloning vector with the DNA sequence of interest is then 
introduced into cells. For bacteria, this process is known as transformation, while the 
same process is termed transfection for mammalian cells. There are various 
methods for transforming bacterial cells (96). The work presented here utilizes 
chemically competent cells, meaning the cells have been treated with chemicals to 
stimulate them to accept plasmids. Once introduced into bacteria cells, the plasmid 
is replicated numerous times. Thus, cloning can be used to produce a large amount 
of the desired plasmid. The plasmid can also serve as a template for transcription of 
a gene of interest. This allows for production of a desired protein in a cell, without 
modifying the genome of the cell. 
PCR and RT-PCR 
PCR and RT-PCR stand for Polymerase Chain Reaction (98) and Reverse 
Transcription-Polymerase Chain Reaction (95), respectively. These reactions allow 
for the exponential amplification of DNA and RNA molecules. A typical PCR reaction 
mix contains a template (a DNA molecule that contains a sequence of interest), two 
oligonucleotide primers (short DNA molecules that are complementary to the 
sequences flanking the region of interest), the four deoxyribonucleotides (called 
dNTPs, where N stands for A, C, T, or G) and a thermostable DNA polymerase (an 
enzyme that catalyzes the polymerization of deoxyribonucleotides). A thermostable 
DNA polymerase maintains its activity at higher reaction temperatures, and these 
DNA polymerases have made PCR automatable. The most common thermostable 
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DNA polymerase was originally isolated from the bacterium Thermus aquaticus and 
is commonly known as Taq polymerase.  
PCR is a 3-step, cyclic process. The first step is denaturation. The reaction 
mix is heated to 95 °C for about 1 min to separate the two strands of the DNA 
template. The second step is annealing, or renaturation. In this step, the reaction 
mixture is cooled to a temperature that allows the oligonucleotide primers to anneal 
to the DNA template (typically around 55 °C). The third step is elongation (or 
synthesis). In this stage, the reaction mixture is heated to around 75 °C, which is the 
optimum reaction temperature for Taq DNA polymerase. The polymerase then 
catalyzes the polymerization of the DNA strand, using the oligonucleotide primers as 
a starting point and progressing in the 3’ direction. The polymerase uses the 
template DNA to direct what nucleotide is added to the growing chain. PCR allows 
for exponential amplification of a template (2n, where n equals the number of cycles), 
with just 30 rounds of PCR resulting in a billion copies of the desired sequence.  
RT-PCR is a similar process, with a few key differences. The initial template 
for RT-PCR is RNA. Before PCR can amplify the sequence of interest, the RNA 
template must be converted into a DNA template. This is done using an enzyme 
known as reverse transcriptase. Reverse transcriptases catalyze the polymerization 
of deoxyribonucleotides to form a DNA strand, but they utilize RNA as their template 
(98). After the initial reverse transcription reaction, the newly formed DNA template 
is used as the template for a standard PCR reaction. In this work, RT-PCR was used 
to amplify the GFP transcripts from the total RNA isolated from in vivo test reactions. 
Site-directed mutagenesis 
Site-directed mutagenesis is a method for altering the sequence of a DNA 
molecule in a sequence-specific manner (96). There are various methods available, 
but the procedure used in this work is similar to PCR (outlined above). Mutagenic 
oligonucleotides containing the desired changes are used as primers, and the DNA 
template is most commonly a plasmid. The reaction mixture is subjected to the PCR 
steps of denaturation, annealing, and polymerization. To isolate selectively the 
mutated plasmid, the template plasmid (with no mutations) is selectively degraded 
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with a restriction enzyme. The reaction mixture is then used to transform E. coli. The 
cells will circularize the mutant PCR products, producing the desired mutant 
plasmids.  
Fluorescence spectroscopy 
The measurement of the concentration of green fluorescent protein relies on 
fluorescence. Fluorescence refers to a pathway by which an excited atom or 
molecule relaxes to its ground state. This relaxation results in the emission of radiant 
energy (99, 100). For GFP, a conjugated pi-system results from the cyclization of the 
side chains of Ser65-Tyr-Gly67 (82, 93). In terms of biological systems, fluorescence 
results from exciting small molecules with these types of extended conjugated pi-
systems. Their chemical resonance frequencies are in the visible spectrum (101). 
Fluorescence spectroscopy involves exciting a sample at a particular wavelength 
(the excitation wavelength) and then detecting the emission at a different 
wavelength. For the in vivo studies outlined in this work, measurements of GFP 
fluorescence were made utilizing a CytoFluor. This instrument uses filters to select 
the wavelength band of the excitation beam and the wavelength band of the 
fluorescence emission. Thus, cells containing GFP in these studies were excited 
using an excitation filter of 485 ± 20 nm (as the maximum excitation wavelength for 
the GFP used in these studies is 475 nm), and fluorescence was detected using an 
emission filter of 508 ± 20 nm (as the maximum emission wavelength of this GFP is 
509 nm).  
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Figure 2.1.  Deoxyribonucleotide 
 
Deoxyribonucleotides are the monomers that make up a DNA strand. Each 
deoxyribonucleotide consists of a phosphate group, a deoxyribose sugar and a 
nitrogenous base. The identity of the nitrogenous base distinguishes each 
nucleotide.  
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Figure 2.2.  The Nitrogenous Bases in DNA 
 
There are four nitrogenous bases found in DNA. Adenine and guanine are 
purine bases, while thymine and cytosine are pyrimidine bases. Each base is 
typically referred to by its single letter abbreviation: A=Adenine, G=Guanine, 
T=Thymine, and C=Cytosine. These single letter abbreviations are also used to 
designate the nucleotides of DNA. 
 16 
Figure 2.3.  Structure of a DNA Strand 
 
A DNA strand results from the polymerization of deoxyribonucleotides. The 
linkage is a phosphodiester bond between the 3’ hydroxyl group of one 
deoxyribonucleotide and the 5’ phosphate group of an adjacent deoxyribonucleotide. 
These linkages are also known as the phosphodiester backbone or the sugar-
phosphate backbone. The formation of linkages in this manner gives the strand 
directionality. As shown, the strand runs in the 5’-to-3’ direction. 
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Figure 2.4.  Double Helix Structure of DNA 
  
Two strands of DNA come together and interact via hydrogen bonding 
between the bases, known as base pairing. The phosphodiester backbones of each 
strand twist around a central helix with the bases of each strand interacting in the 
middle. This gives the double helix the appearance of a ladder, with the base pairs 
acting as the “rungs”. The two strands run in the opposite directions and are called 
antiparallel. 
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Figure 2.5.  Watson-Crick Base Pairing in DNA 
 
The normal base pairing interactions (as shown) are the Watson-Crick base 
pairs and result from adenine base pairing with thymine via two hydrogen bonds (top 
pair) and guanine base pairing with cytosine via three hydrogen bonds (bottom pair). 
The Watson-Crick base pairs are isosteric, meaning they are the same shape. This 
allows for the continuity of the double helix, regardless of the order of the 
nucleotides. Note the antiparallel orientation of the backbones. 
 19 
Figure 2.6.  Central Dogma of Molecular Biology 
 
DNA, the genetic storage material in a cell, is replicated to pass genetic 
information to progeny. DNA also serves as the template for transcription to produce 
RNA. RNA serves as the template for translation to produce protein (a functional 
gene product). 
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Figure 2.7.  Ribonucleotide 
 
Ribonucleotides are the monomers that make up an RNA strand. Each 
ribonucleotide consists of a phosphate group, a ribose sugar, and a nitrogenous 
base. The identity of the nitrogenous base distinguishes each nucleotide. A key 
difference between the nucleotides found in DNA and the nucleotides found in RNA 
is the presence of a hydroxyl group on the 2’ position of the ribose sugar (boxed in 
red). 
 21 
Figure 2.8.  Uracil 
 
The base thymine in DNA is replaced by uracil in RNA. The difference 
between thymine and uracil is the absence of a methyl group in uracil. Uracil is 
typically referred to by its single letter abbreviation of U. 
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Figure 2.9.  Examples of RNA Secondary Structure 
 
RNA is synthesized single stranded (top left); however, it has the ability to 
base pair and to form structures. Examples include double stranded RNA, a hairpin 
loop, and a single base bulge. Double stranded RNA results from two RNA strands 
interacting via base pairing, similar to the DNA double helix structure. The formation 
of a hairpin results from a single strand folding on itself to form a base paired stem 
connected by a loop of unpaired nucleotides. A single base bulge results from two 
strands forming a double stranded interaction, but a base in one strand lacks its 
base pairing partner in the opposing strand. This causes the unpaired base to bulge 
out. 
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Figure 2.10.  Self-Splicing of Group I and Group II Introns 
 
General schematics of the self-splicing reactions of group I (left) and group II 
(right) introns. For both diagrams, the 5’ exon is blue, the 3’ exon is red and the 
catalytic introns are gray. For group I introns, the first cleavage step is mediated by 
an exogenous guanosine cofactor (shown in green) that binds a particular site in the 
intron. The 3’ hydroxyl of the guanosine cofactor performs a nucleophilic attack at 
the 5’ splice site, resulting in cleavage of the phosphodiester backbone and 
attachment of the G cofactor to the free end of the intron. For group II introns, the 
first cleavage step is mediated by the 2’ hydroxyl of an adenosine in the intron and 
results in the formation of a lariat structure. For both introns, the 3’ hydroxyl on the 
end of the 5’ exon then performs a second nucleophilic attack at the 3’ splice site. 
This attack ligates the exons together and releasing the introns. The free group I 
intron can undergo a cyclization reaction via a nucleophilic attack by the terminal 
guanosine. 
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Figure 2.11.  Predicted Secondary Structure of the Pneumocystis carinii Self-
Splicing Group I Intron 
 
Predicted secondary structure of the self-splicing group I intron from an rRNA 
from the opportunistic pathogen Pneumocystis carinii. The above structure was 
adapted from (11). The 5’ exon sequence is shown in lowercase, blue lettering; the 
3’ exon sequence is shown in lowercase, red lettering; and the intron sequences are 
in uppercase, black lettering. The recognition elements of the intron (RE1, RE2, and 
RE3) and their base-pairing partners (which form the P1, P9.0, and P10 helices, 
respectively) are enclosed in gray. The guanosine binding site, in helix P7, is 
indicated by the gray oval. The cleavage sites for the first and second reaction steps 
of self-splicing are designated by numbered arrows. 
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 Figure 2.12.  Self-Splicing Reaction of a Group I Intron 
 
Detailed schematic of the group I intron self-splicing reaction. The 5’ exon is 
shown in blue, the 3’ exon is red, and the catalytic intron is gray. The intron initially 
folds on itself and makes contact with the 5’ and 3’ exons. Three important targeting 
interactions result from base pairing between sequences in the intron (termed 
recognition elements, RE) and the 5’ exon (RE1; to form the P1 helix), the 3’ exon 
(RE3; to form the P10 helix) and another sequence within the intron (RE2; to form 
P9.0). An exogenous guanosine nucleotide (shown in green) binds a particular site 
in the intron (known as the guanosine binding site) and the 3’ hydroxyl group of this 
nucleotide performs a nucleophilic attack at the 5’ splice site in the first reaction step. 
The phosphodiester backbone is cleaved at the 5’ splice site, resulting in a 3’ 
hydroxyl on the terminal nucleotide of the 5’ exon (typically a uridine; shown as a 
blue circle). The guanosine cofactor becomes attached to the end of the intron.  
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In the second reaction step, the 3’ hydroxyl on the terminal uridine of the 5’ 
exon performs a nucleophilic attack at the 3’ splice site, immediately after a 
guanosine that defines the end of the intron (referred to as ωG; shown as a gray 
circle). This attack results in ligation of the two exons and release of the intron. 
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Figure 2.13.  Predicted Secondary Structure of the Pneumocystis carinii 
Ribozyme 
 
Predicted secondary structure of the Pneumocystis carinii ribozyme base 
pairing with exogenous substrate mimics of the native 5’ and 3’ exon sequences.  
The above structure was adapted from (22). The recognition elements (RE1, RE2 
and RE3) are highlighted in gray and are shown base pairing to the 5’ exon (shown 
in blue), a segment mimicking a portion of the native intron (shown in lowercase, 
black lettering), and the 3’ exon (shown in red) to form the P1, P9.0 and P10 helices, 
respectively. The G-binding site in helix P7 is enclosed in a gray oval. The arrow 
designates the nucleophilic attack that results in exon ligation (the second reaction 
step of self-splicing). 
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Figure 2.14.  Trans Excision-Splicing Reaction 
 
Detailed schematic of the trans excision-splicing reaction (22). The 5’ exon is 
in blue, the 3’ exon is in red, and the TES ribozyme is in gray. The sequence 
targeted for excision is a broken line. The recognition elements from the self-splicing 
intron are used for target recognition. RE1 base pairs with the 5’ exon (to form the 
P1 helix), RE3 base pairs with the 3’ exon (to form the P10 helix) and RE2 base 
pairs with the insert (when longer than a single nucleotide) targeted for excision (to 
form P9.0). A hydroxyl group (most likely from a water molecule bound to the 
ribozyme) performs a nucleophilic attack at the 5’ splice site in the first reaction step. 
The phosphodiester backbone is cleaved, resulting in a 3’ hydroxyl on the terminal 
nucleotide of the 5’ exon (typically a uridine; shown as a blue circle). In the second 
reaction step, the 3’ hydroxyl of the terminal nucleotide of the 5’ exon performs a 
nucleophilic attack on the 3’ splice site, immediately after a guanosine that defines 
the end of the insert region (termed ωG; shown as a gray circle). This results in exon 
ligation and release of the excised segment and the ribozyme. 
 29 
CHAPTER 3 - DETERMINATION OF THE SPLICE SITE SEQUENCE 
REQUIREMENTS FOR THE TRANS EXCISION-SPLICING RIBOZYME 
 
Proposed Project 
Previous work with the trans excision-splicing ribozyme has demonstrated 
that the recognition elements of the ribozyme can be changed to target different 
substrates (22, 32). In those studies, as well as studies looking at the molecular 
recognition of the Pneumocystis carinii intron in the related suicide inhibition (11, 31) 
and reverse cyclization (31) reactions, two highly conserved elements from self-
splicing group I introns were maintained. These elements are the formation of a u-G 
wobble pair (Figure 3.1) at the -1 position of the P1 helix to define the 5’ splice site 
(11, 22, 59, 68, 73, 102, 103) and a guanosine as the last nucleotide of the 
sequence to be excised (Figure 3.2). This guanosine corresponds to the last 
nucleotide of the intron (called ωG) in the self-splicing reaction and has been shown 
to be a critical component of the exon ligation reaction (60, 104-109). Note that 
throughout this chapter, lowercase nucleotide abbreviations refer to the substrate, 
uppercase lettering refers to the ribozyme, and the 5’ splice site refers to the base 
pair that forms between position 12 of the ribozyme and the –1 position of the 
substrate (11). If these sequence requirements at the 5’ and 3’ splice sites are 
absolute, trans excision-splicing ribozymes will be limited in what sequences they 
can target for excision. 
Previous work with other group I introns and their derived ribozymes 
demonstrated that the sequence requirements at these splice sites may not be 
stringent. It had been shown that the c-A wobble pair can be a substitute for the u-G 
wobble pair at the 5’ splice site in the 5’ cleavage reaction (59), and c-G can act as a 
substitute in the self-splicing reaction (102, 110). In these cases, product yields were 
reduced and the reaction rates were slower than when u-G is present. It has also 
been reported that ωG can be changed to ωA, with either no change required to the 
catalytic core (72) or by modifying the guanosine binding site (GBS) of the ribozyme 
in a particular way to accommodate adenosine (60, 111). Most of the above 
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mentioned results were obtained from work on the well-studied self-splicing group I 
intron and ribozyme from Tetrahymena thermophila (1). Previous work with the P. 
carinii ribozyme indicated some differences in substrate recognition compared to the 
Tetrahymena ribozyme (11, 112-115). Therefore, I worked with another member of 
the Testa lab, Joy Sinha, to analyze the 16 possible base pair combinations at the 5’ 
splice site and the four nucleotides found in RNA at the ω position at the 3’ splice 
site in the context of the TES reaction. We utilized our simplest TES system in which 
a single nucleotide is excised from an RNA substrate. The excision of a single 
nucleotide does not utilize RE2 for targeting, so the number of recognition elements 
is limited to two. Also, the single nucleotide that is targeted for excision is analogous 
to the ω position in group I introns. Utilizing this simple system limits the number of 
reaction variables and simplifies the analyses. These studies were undertaken to 
provide a more thorough understanding of the sequence requirements for the TES 
reaction, specifically at the 5’ splice site and for the ω position of the 3’ splice site. 
This information will be useful in developing guidelines for what sequences the 
ribozymes can target, what sequences the ribozymes can excise, and how specific 
these reactions might be (relative to each other). These studies will also provide 
insight into the molecular recognition of the splice sites by this P. carinii ribozyme. 
Materials and Methods 
Nucleic acid synthesis and preparation 
DNA oligonucleotides for site-directed mutagenesis were purchased from 
Integrated DNA Technologies (Coralville, IA) and used without further purification. 
RNA oligonucleotides were purchased from Dharmacon Research Inc. (Boulder, 
CO) and deprotected following the manufacturer’s recommended protocol. The 
manufacturing process leaves a protecting group on the 2’ hydroxyl groups of RNA 
oligonucleotides, which must be removed prior to using the molecules.  
Radiolabeling RNA oligonucleotides 
Designated RNA oligonucleotides were 5’ end-radiolabeled with T4 
polynucleotide kinase (New England Biolabs; Beverly, MA) and [γ32P]-ATP 
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(Amersham Pharmacia Biotech; Piscataway, NJ) and purified on a 20% native 
polyacrylamide gel, as previously described (32). Designated RNA oligonucleotides 
were also 3’ end-radiolabeled using a modified version of a two-step procedure 
previously described (97). Cytidine monophosphate (Cp) was radiolabeled at the 5’ 
terminus by incubating 10 μM Cp, 0.85 μM [γ-32P] ATP (Amersham Pharmacia), 70 
mM Tris-HCl (pH 7.5), 50 mM KCl, 10 mM MgCl2, 5 mM dithiothreitol (DTT), 0.1 mM 
EDTA, 0.1 mM ATP, 10% glycerol and 10 units T4 polynucleotide kinase (New 
England Biolabs) in a reaction volume of 10 μL for 1.5 h at 37 °C. The kinase was 
heat-inactivated at 65 °C for 15 min. Next, the prepared *pCp was ligated to the 3’ 
end of the designated RNA substrates in a reaction containing 2 μM RNA substrate, 
0.28 μM *pCp, 50 mM Tris-HCl (pH 7.4), 50 mM KCl, 10 mM MgCl2, 10 mM DTT, 1 
mM ATP, 0.1 mM EDTA, 10% dimethyl sulfoxide (DMSO), and 20 units of T4 RNA 
ligase (New England Biolabs). Ligation reactions proceeded at 4 °C for at least 16 
hours. The labeled substrates were then gel purified by the same method as the 5’ 
end-labeled substrates listed above.  
Ribozyme preparation 
The P. carinii ribozyme plasmid precursor, P-8/4x, was previously constructed 
as described (11). Modifications to alter the guanosine in the 12 position of the 
ribozyme that is involved in the wobble pair at the 5’ splice site and to delete the 
RE3 sequences that are involved in P10 formation were made using site-directed 
mutagenesis. The following pairs of primers were used for altering the ribozyme at 
the 12 position (underlined base represents the altered bases as compared to P-
8/4x): 5’CGACTCACTATAGAGCGTCATGAAAGCGGC3’ and 
5’GCCGCTTTCATGACGCTCTATAGTGAGTCG3’ to create P-8/4x-5’C; 
5’CGACTCACTATAGAGAGTCATGAAAGCGGC3’ and 
5’GCCGCTTTCATGACTCTCTATAGTGAGTCG3’ to create P-8/4x-5’A 
5’CGACTCACTATAGAGTGTCATGAAAGCGGC3’ and 
5’GCCGCTTTCATGACACTCTATAGTGAGTCG3’ to create P-8/4x-5’U. The following 
primer pair was used to create P-8/4x-noP10: 
5’CGACTCACTATAGGTCATGAAAGCGGC3’ and 
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5’GCCGCTTTCATGACCTATAGTGAGTCG3’. The site-directed mutagenesis 
reactions were performed as previously described (22), with some modifications. 
The reaction mixtures were first subjected to denaturation at 95 °C for 30 s, followed 
by 16 temperature cycles of 95 °C for 30 s, either 50 °C or 60 °C for 2 min, and 68 
°C for 6 min. The parental plasmids were then digested with 20 units of DpnI 
(Invitrogen; Carlsbad, CA) in 4.2 μL of manufacturer’s buffer for at least 2 h at 37 °C. 
A 3-μL aliquot of this mixture was then used to transform Escherichia coli DH5α 
chemically competent cells (Invitrogen). The resultant plasmids were purified using a 
QIAprep Spin Miniprep kit (QIAGEN; Valencia, CA), and sequenced to confirm the 
changes (Davis Sequencing; Davis, CA). 
Prior to transcription, plasmids were linearized by restriction enzyme digest 
with XbaI and purified from the reaction mixture using a QIAquick PCR Purification 
kit (QIAGEN). Transcription and purification of the ribozymes proceeded as 
previously described (22). 
Trans excision-splicing reactions 
Trans excision-splicing reactions were conducted under conditions previously 
optimized for the reaction containing a u-G wobble pair at the 5’ splice site (22). This 
involved running the reactions at 44 °C in H10Mg buffer, which consists of 50 mM 
Hepes (25 mM Na+), 135 mM KCl, and 10 mM MgCl2 (from 0 mM to 15 mM when 
using the rP-8/4x-noP10 ribozyme) at pH 7.5. Prior to each reaction, 166 nM 
ribozyme in 5.0 μL of H10Mg buffer was preannealed at 60 °C for 5 min and then 
slow cooled to 44 °C. The reactions were initiated by adding 1.0 μL of an 8 nM 
solution of 5’ end radiolabeled or 3’ end radiolabeled substrate in H10Mg buffer. The 
Kd of the substrate is expected to be approximately 5.2 nM, similar to the Kd of the 6-
mer 5’ exon mimic (11). Reaction times for the TES reactions investigating the 5’ 
splice site were 15 min and 1 h. The 3’ splice site studies and the rP-8/4x-noP10 
reactions were allowed to proceed for 1 h. Time dependence assays to determine 
the source of cryptic products were run from 1 min to 120 min. All reactions were 
terminated by adding an equal volume of stop buffer (10 mM urea, 0.1X TBE, and 3 
mM EDTA). The products and reactants were denatured at 90 °C for 1 min prior to 
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loading on a 12.5% polyacrylamide/8M urea gel for separation. Following 
electrophoresis, the gel was transferred to chromatography paper (Whatman 3MM 
CHR) and dried under vacuum for 1 h at 70 °C. The dried gels were exposed to 
phosphorescence screens overnight. Reaction products were then visualized and 
quantified using a Molecular Dynamics Storm 860 PhosphorImager. All the data 
reported are the average of at least two independent assays.  
Competition assays 
166 nM ribozyme was preannealed in H10Mg buffer for 5 min at 60 °C. The 
ribozyme was then slow cooled to 44 °C, at which point 1.3 nM of the radiolabeled 
substrate in H10Mg buffer was added to initiate the reaction. After 5 min, 1000-fold 
excess of unlabeled TES product competitor (over substrate) in H10Mg buffer was 
added to the reaction mixture. Periodically, an aliquot was removed and added to an 
equal volume of stop buffer over a period of 90 min, starting 10 min after addition of 
the competitor (15 min after reaction initiation). The substrates and products were 
denatured by heating at 90 °C for 1 min prior to gel loading, and the products were 
separated, visualized, and quantified as described above. 
Results 
Molecular recognition at the 5’ splice site 
Four different 10-mer substrates, 5’augacygcuc3’ (where y stands for u, g, c, or 
a), were utilized with four different ribozymes, each containing a different nucleotide 
at position 12 of the ribozyme (shown in white lettering in Figure 3.3). This allowed 
us to test all 16 possible base pair combinations at the 5’ splice site. We chose to 
use our simplest TES target system, in which a single nucleotide (analogous to ωG) 
is excised from within the substrates. Using this system means that one of the 
recognition elements, RE2, is not utilized in the reaction as it cannot base pair with 
the substrate to form P9.0 due to a lack of complementary bases (Figure 3.3). The 
reaction conditions used were previously optimized for the TES reaction using the 
10-mer substrate and ribozyme that would reconstitute the conserved u-G wobble 
pair found at the 5’ splice site (22). This initially included running the reactions for 1 
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h. Under these conditions, all 16 base pair combinations gave first-step product (5’ 
cleavage via hydrolysis), although the extent of reaction varies significantly as a 
function of sequence (Figure 3.4). It should be noted that the yield of the first step is 
the combined total of the first and second steps of the reaction as the product of the 
second reaction step must necessarily have undergone the first reaction step. This 
total is represented by the sum of the black bars and the white bars of the graph in 
Figure 3.4.  
Unexpectedly, multiple sequence combinations gave an appreciable amount 
(>10%) of complete TES product (black bars on the graph; Figure 3.4). There were 
also cases (u-A, a-U, c-G, g-C, and c-C) that produced appreciable amounts of 
cryptic products which were shorter than the 9-mer TES product. The total 
percentage of all cryptic products formed for a base pair are shown as gray bars on 
the graph in Figure 3.4. We decided to investigate the 16 base pair combinations 
further by running time dependent assays to determine when the cryptic products 
appear. These assays allowed us to find a reaction time that minimized cryptic 
product formation while still producing appreciable amounts of TES product.  
The results of the time dependence assays fell into three classes. In the first 
class, which consisted solely of those combinations that put Watson-Crick base 
pairs at the 5’ splice site, cryptic products appear after 15 min (represented by c-G; 
Figure 3.5A). In the second class, consisting only of c-C, cryptic products appear 
much earlier (after 1 min) and to a greater extent than the other combinations 
(Figure 3.5B). In the third class, consisting of all other non-Watson-Crick 
combinations, appreciable cryptic products do not appear, even in cases where 
substantial TES products form (represented by u-G; Figure 3.5C). These results 
indicate there are two possible routes to cryptic product formation. For the Watson-
Crick pairs, cryptic products appear to be formed after TES product formation. For c-
C, cryptic product formation appears to occur shortly after substrate binding. As c-C 
never produced appreciable amounts of TES product, it was not investigated in 
further detail. Based on these studies, we looked at the 5’ splice site sequences in 
the TES reaction using 15 min as the reaction endpoint.  
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When comparing the results from the 15 min and 1 h reactions, the trends 
with regard to the yield of TES products formed were very similar (compare Figures 
3.4 and 3.6). There was, however, a noticeable difference in the production of cryptic 
products, as they were effectively removed for the Watson-Crick pairs at the shorter 
reaction time. Again, multiple sequence combinations gave an appreciable amount 
(>10%) of complete TES product (Figure 3.6). These include the u-G and c-A 
wobble pairs, all four Watson-Crick base pairs, and the a-G combination. The 
conserved u-G wobble pair was the most effective, producing 68% TES product, 
with the c-A wobble pair being the next highest (43%). These results were not 
surprising as it was previously known that these wobble combinations were 
acceptable at this position in other introns (59). What was surprising was that all four 
Watson-Crick base pairs produce a relatively high amount of product (>25%). These 
results were in contrast to results for Tetrahymena ribozymes in terms of 5’ cleavage 
(59, 102). Studies looking at exon ligation in Tetrahymena indicated other 
combinations were allowable (102), but not all nucleotides worked in the -1 position 
of the 5’ exon, as was the case in our studies. 
While the TES product from reactions with the 10-mer substrate with a u-G at 
the 5’ splice site had previously been enzymatically sequenced to ensure it was the 
expected TES product (22), it was important to ensure that all the observed TES 
products resulted from the excision of the targeted internal guanosine. If the 
substrate bound the ribozyme in a misaligned register, a 9-mer product could form if 
the 3’ c of the substrate was cleaved off in the first reaction step. To confirm that this 
misalignment was not occurring in any of the sixteen 5’ splice site cases, TES 
reactions were run using substrates that contain a radiolabeled nucleotide added to 
the 3’ end of the 10-mer substrates (to give 11-mer substrates). The radiolabel is 
now on the opposite end of the substrate and an alternate pathway to the 9-mer 
“product” involving the cleavage of the 3’ c would result in the production of a 
radiolabeled 2-mer (the 3’ c with the additional radiolabeled nucleotide on the 3’ 
end). As seen in Figure 3.7, no 2-mer products are formed. However, we get 10-mer 
bands, representing the TES product (the 9-mer product with the additional 
radiolabeled nucleotide on the 3’ end). When combining our results from the 5’ 
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labeled substrates and the 3’ labeled substrates, we see that the reaction end-
products all contain both the 5’ and 3’ ends of their substrates and their products are 
a single nucleotide shorter. This indicates the ribozymes are excising an internal 
segment. As the intermediates do not vary in size and are the expected 6-mers (for 
the 5’ labeled substrates), a different base is not being utilized as the ω base.  
The results showed that the sequence of both the exon and the ribozyme (at 
the 5’ splice site) is important for each reaction step. Guanosine is favored at the 12 
position of the ribozyme, with all four possible combinations giving over 60% first 
step product (5’ cleavage) and only the g-G combination producing less than 10% 
TES product during the 1 h reaction. These results are perhaps not unexpected as a 
guanosine in this position is the native form of the intron. Cytidine in either the 
ribozyme or the substrate is unfavorable for TES product formation, unless it is 
involved in a Watson-Crick base pair or a c-A wobble pair. We also found that a high 
level of first step (hydrolysis) product does not necessarily lead to a high level of 
TES product. This is seen when adenosine is present at the –1 position in the 
substrate. Adenosine in the substrate leads to at least 30% first step reactivity with 
all four ribozymes in the 15 min reactions, but only a-U and a-G lead to significant 
amounts of TES product (Figure 3.6). By looking at the thermodynamic stability of 
the different base pair combinations (116), those base pairs expected to be more 
stable, such as the Watson-Crick base pairs and the wobble pairs, produce 
significant amounts of TES product. These results indicate a stable base pair is 
required for the second reaction step (exon ligation) to proceed efficiently. 
Source of cryptic products 
We found it interesting that of all the combinations that produced substantial 
TES product, only the Watson-Crick pairs led to cryptic products at extended 
reaction times. We wanted to determine the source of these cryptic products. To this 
end, we ran time dependent TES assays utilizing a 6-mer, which mimics the 5’ exon 
product of the 5’ cleavage reaction, and a 9-mer, which mimics the expected TES 
product, as the reaction substrates. Since the cryptic products do not appear until 
after the reactions have been running for 15 min, we know the cryptic degradation is 
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not occurring with the 10-mer substrates. If the degradation is occurring prior to exon 
ligation (the second reaction step), we expect the 6-mer to be degraded. If the 9-mer 
is degraded, then the TES products are being degraded after the second reaction 
step. For these assays, we utilized two representative ribozyme-substrate 
combinations, the u-A pair (Figure 3.8) and the c-G pair (data not shown). Only the 
9-mer was degraded in these assays, indicating that the cryptic products are 
produced from cleavage of the TES products themselves, and not the 5’ exon 
intermediate of the first step of the TES reaction. This explains why cryptic products 
only occur at relatively long reaction times, as there must be production of TES 
product before cryptic hydrolysis occurs. The products are not only cleaved at the 
cryptic sites, but also at the original 5’ splice site (producing the 6-mer intermediate; 
Figure 3.8), showing that some amount of TES products for all base pair 
combinations are likely recleaved at the correct 5’ splice site. 
Once we determined the source of the cryptic products, we decided to 
investigate the mechanism of cryptic product formation. There are two possible 
routes to cryptic product formation. The first route involves the newly formed TES 
product staying bound to the ribozyme, but changing binding registers. If there was a 
shift in the binding register, a new site could be positioned for 5’ cleavage within the 
catalytic core of the ribozyme. There are two ways this shift could occur. The 5’ exon 
could slip relative to the RE1 sequence of the ribozyme, leading to mispairing 
between the exon and RE1 and putting a different exon nucleotide at the -1 position 
for 5’ cleavage (102). The second way this shift could occur is that the helix formed 
by the product base pairing to RE1 and RE3 of the ribozyme, which is a continuous 
helix after the removal of the targeted nucleotide from the substrate and is called P1 
extended [or P1ex (32)], translocates through the catalytic core of the ribozyme. This 
translocation would put a new base pair in position for 5’ cleavage (59, 63, 103). The 
second route to cryptic product formation involves dissociation of the product from 
the ribozyme. The product is then able to rebind the ribozyme, and, by either 
mispairing or by translocation (as described above), presents different positions on 
the product for the 5’ cleavage reaction.  
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To distinguish between these possible routes, we conducted competition 
assays. In these assays, a large excess of unlabeled TES product was added to 
TES reactions before cryptic products started to form. If the product dissociates and 
rebinds prior to cryptic product formation, the excess unlabeled product will out 
compete the labeled product for rebinding free ribozyme. This competition would 
lead to a decrease in the amount of cryptic degradation seen in the labeled material. 
If the product does not dissociate prior to cryptic product formation, the excess 
competitor will have no affect and the amount of cryptic products formed will remain 
the same relative to product formation. Once again, we studied two representative 
pairs, the u-A pair (Figure 3.9) and c-G pair (data not shown) at the 5’ splice site. We 
utilized combinations that produce cryptic products instead of those combinations 
that did not produce cryptic products (such as the u-G or c-A wobble pairs) to allow 
us to differentiate between the 5’ exon intermediate produced from the TES 
substrates and the cryptic products produced from the TES products. As seen in 
Figure 3.9 (representing the u-A pair), by adding excess competitor, we almost 
completely eliminate the cryptic products. This result indicates the TES products are 
dissociating and then rebinding free ribozyme. Once the products bind the ribozyme, 
they are subjected to 5’ cleavage to produce cryptic products (as seen for the u-A 
pair in Figure 3.8, data not shown for c-G). 
Molecular recognition at the 3’ splice site 
To look at the sequence requirements at the 3’ splice site, we used another 
simple substrate-ribozyme system that was similar to the system we used to look at 
the 5’ splice site. Once again, a single nucleotide was targeted for excision. This 
nucleotide, which corresponds to the ω position within self-splicing introns, was 
altered in four different 10-mer substrates (5’augacuxcuc3’, where x=G, C, A, or U) to 
test each nucleotide in the ω position (Figure 3.10). These substrates were tested 
with the native ribozyme (containing a u-G wobble pair at the 5’ splice site) for TES 
reactivity. Typically, the ω position defines the 3’ splice site by binding to the 
guanosine binding site (GBS) of the catalytic core of the ribozyme (104, 109). For 
TES systems that excise a region longer than a single nucleotide, the ω position is 
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the last base of the excised region (22). The first step of the TES reaction (5’ 
cleavage) occurs in all four cases (white bars on the graph; Figure 3.10), with the 
greatest amount of 5’ cleavage occurring when guanosine is the ω base. For second 
step reactivity, and thus complete TES product formation, guanosine is absolutely 
required at the ω position (black bar on the graph; Figure 3.10). We tried to rationally 
redesign the GBS of the ribozyme based on work that was done with Tetrahymena 
ribozymes (60, 111), but these changes did not alter the specificity at the ω position 
(data not shown). These results indicate the mode of molecular recognition of the ω 
position base by the GBS may not be the same between the two ribozymes. Thus in 
its current incarnation, the TES ribozyme requires guanosine in the ω position. 
The ωG is not the only determinant of the 3’ splice site. The P9.0 helix, which 
forms between elements of the intron itself in the self-splicing reaction, and the P10 
helix, which forms between the intron and the 3’ exon, flank the ω position (Figure 
3.2) and are also important elements for 3’ splice site recognition (60, 76, 104-109, 
117-119). For the TES reactions where a single nucleotide is excised, P9.0 helix 
formation is not possible (Figure 3.3) or required (22). The binding of ωG to the GBS 
is predicted to be a weak interaction (52, 76, 118), so we expected that P10 
formation would be critical for TES product formation as it would be involved in 
holding the 3’ intermediate of the first reaction step prior to exon ligation. To test this, 
we created a ribozyme that lacked the RE3 sequences, which prevents P10 
formation (rP-8/4x-noP10). Surprisingly, TES product was formed in the absence of 
P9.0 and P10 formation, albeit in low yield (black bars on the graph in Figure 3.11). 
Therefore, ωG is sufficient as a 3’ molecular recognition element for TES reactions, 
although P10 and P9.0 are beneficial. 
Discussion 
Molecular recognition at the 5’ splice site  
In nature, a u-G wobble pair is almost universally conserved at the 5’ splice 
site of self-splicing group I introns. The only known exceptions are c-G pairs that 
exist for translational coding purposes, as changing these c-G pairs to u-G pairs 
lowered the magnesium requirements of the self-splicing reaction and increased the 
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reaction rate (110). The TES ribozyme is derived from a group I intron, so one of the 
expected sequence limitations of the TES reaction is the requirement for either a u-
G pair (11, 22, 59, 68, 73, 102, 103) or possibly a c-G base pair (110) at this 
position. In these cases, a guanosine is present at position 12 of the ribozyme 
(located in RE1), and uridine or cytidine is at the –1 position of the substrate (Figure 
3.2). For group I intron-derived ribozymes, it has also been reported that the c-A 
wobble pair allows the 5’ cleavage reaction, although it is not nearly as effective as 
u-G pairs (59). Other base pairs and mismatch combinations do not work at all (59) 
or to a very small extent (102, 120). The c-A substitution is most likely allowable 
because c-A can form a wobble base pair with a spatial orientation and accessibility 
of free functional groups analogous to that of u-G pairings (42, 59, 70, 121). A 
wobble pair may also help to define the 5’ splice site by distorting the backbone 
structure in the P1 helix. X-ray crystallography studies on tRNA (122, 123) and an 
NMR structure of a model of a P1 helix (124) showed that a u-G wobble pair 
perturbs an RNA helix by positioning U closer to the helix axis and G away from it. It 
is believed the distorted backbone of the wobble pairs is accessible for nucleophilic 
attack in the 5’ cleavage reaction, which helps to determine the correct 5’ splice site. 
Also, for the Tetrahymena ribozyme, the free exocyclic amine group of guanosine (at 
ribozyme position 12) in the minor groove is believed to be involved in tertiary 
interactions that help the ribozyme recognize the correct splice site (68, 70, 73). It 
must be noted, however, that there are significant differences in molecular 
recognition between different introns. For example, the measured contribution of the 
u-G wobble pair to tertiary interactions is greater for the P. carinii ribozyme than for 
Tetrahymena (113) and Candida albicans (114). Moreover, the 2’-hydroxyl groups of 
the ribose sugar of the nucleotides have been shown to take part in binding of 
Tetrahymena substrates (125-129), yet these interactions do not appear to be critical 
for P. carinii-derived ribozymes (11). Due to these differences, identifying and 
understanding the sequence requirements for P. carinii ribozymes is useful for 
developing effective and specific TES ribozymes. To this end, we have tested the 
effectiveness of each of the 16 possible base combinations at the 5’ splice site in the 
TES reaction. 
 41 
We report that all 16 base pair combinations undergo the first reaction step (5’ 
cleavage), while the u-G and c-A wobble pairs, all four Watson-Crick pairs, and the 
a-G pair go on to produce appreciable amounts of TES product (>10%). These 
results, particularly in terms of the first reaction step (5’ cleavage), suggest that the 
interactions involved in 5’ splice site determination are not stringent. This substrate 
promiscuity at the 5’ splice site was unexpected, and is in contrast to results 
reported for analogous reactions using a Tetrahymena ribozyme (59, 102). 
Apparently, for P. carinii-derived ribozymes, identification of the 5’ splice site is not 
entirely dependent on having specific functional groups in the ribozyme at position 
12 or the substrate at -1. That 7 out of 16 combinations give an appreciable amount 
of TES product, including all four Watson-Crick base pairs, suggests unexpectedly 
lax sequence and structural requirements at the 5’ splice site. Some general trends 
to note include a preference for a purine (G or A) in the 12 position of the ribozyme, 
a strong benefit for the u-G pair, and the appearance of substantial amounts of 
cryptic products at extended times for the Watson-Crick pairs. It is interesting that 
although u-G and c-A give substantial amounts of TES product, switching the 
location of the pairs (to produce g-U and a-C) did not produce significant amounts of 
TES product (Figures 3.4 and 3.6). Apparently, it is not just the presence of a wobble 
pair that is beneficial for the TES reaction, but the presence of a wobble pair with a 
purine in the ribozyme and a pyrimidine in the substrate. 
Note that effective 5’ cleavage, however, does not necessarily translate into 
high levels of TES product. For example, base combinations a-A, a-C, and g-G 
produce reasonable amounts of 5’ cleavage product, yet they each produce only 
about 2% TES product (Figure 3.4). These base pairing combinations are expected 
to be thermodynamically weak, especially in relation to the wobble pairs and the 
Watson-Crick pairs (116). Therefore, these results indicate that after 5’ cleavage, a 
thermodynamically stable base pair at the 5’ splice site, although not required, is 
beneficial for the exon ligation reaction, perhaps to orient the newly created 3’ 
hydroxyl group on the end of the 5’ exon more favorably for the second reaction 
step. Previous work with the Tetrahymena ribozyme supports this idea (102). 
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Relative effectiveness of each base in each position of the 5’ splice site 
Because multiple base pair combinations at the 5’ splice site give a 
substantial amount of TES product, and because all combinations give some 
amount of first step product, it is worth considering the relative specificity of targeting 
different substrate sequences with the different ribozymes. Table 3.1 (top) shows the 
relative specificity for each ribozyme construct and (bottom) the relative specificity 
for each base at the –1 position in the substrate. These results show that there are 
distinctive combinations of substrate and ribozyme that work much better in the TES 
reaction relative to similar combinations. In terms of the ribozyme, a cytidine is very 
specific for targeting a guanosine in the substrate, as virtually no TES product is 
formed with this ribozyme when targeting cytidine, adenosine, or uridine at the 
corresponding substrate position. Note that we would still get a substantial amount 
of hydrolysis products, however, ribozyme reconstruction methods have been 
developed that could be used to help overcome this problem (32). Uridine in the 
ribozyme has the next highest specificity, then guanosine, and lastly adenosine. 
Adenosine is interesting in that it will target substrates with uridine and cytidine 
approximately equally. The lower specificity of guanosine and adenosine in the 
ribozyme might not be surprising as they are effective in their Watson-Crick base 
pairing combinations (c-G and u-A), as well as in their wobble pair configurations (as 
u-G and c-A). In terms of the substrate position, to target a guanosine in the 
substrate, cytidine is the overwhelmingly best choice for the corresponding ribozyme 
position. When targeting an adenosine, uridine is the best choice and when targeting 
a uridine, guanosine is the best choice. When targeting a cytidine, adenosine is the 
best choice (even better than a guanosine), indicating the importance of forming a 
wobble pair at the 5’ splice site. If one has the flexibility to choose any substrate 
base, using a cytidine in the ribozyme to target a guanosine in the substrate would 
appear to give the most specific TES product (although not necessarily the highest 
yield). Note that this analysis does not take into account the amount of product 
subjected to degradation via cryptic hydrolysis. While a Watson-Crick base pair may 
be beneficial in terms of specificity (such as for g-C), such a base pair combination 
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would not be a good choice due to the high level of cryptic degradation of products 
(~40% in the 1 h reactions, Figure 3.4). 
Molecular recognition at the 3’ splice site  
We looked at the molecular recognition of the 3’ splice site by altering the 
base at the ω position, which is the base excised from the 10-mer substrate (Figure 
3.10). Any of the four bases at the ω position allowed 5’ cleavage (the first reaction 
step); however, the second reaction step (exon ligation) was completely inhibited 
when ωG was replaced with the other bases (Figure 3.10). Thus, the ω position 
must be a guanosine for complete TES product formation, probably due to a 
requirement for specific binding of the ω position base with the GBS. Since any base 
can be utilized for the first reaction step, this indicates that the GBS only comes into 
play in the second reaction step. These results show that, in their current 
incarnation, P. carinii-derived TES ribozymes require a guanosine as the last (or 
only) base to be excised in the substrate. Alteration of this specificity most likely will 
require changes to the GBS of the ribozyme. The GBS of the Tetrahymena ribozyme 
has been altered to change the specificity from guanosine to adenosine (60, 111), 
however, these same mutations did not produce a change in specificity for the P. 
carinii ribozyme (data not shown). One possible explanation is that there is a 
difference in the recognition of the ωG by the Tetrahymena and P. carinii ribozymes. 
P9.0 and P10 are not required for TES reactions  
Of the three known elements that can aid in the molecular recognition of the 
3’ splice site in group I intron self-splicing reactions (ωG, P10, and P9.0), only ωG 
and P10 are present in TES reactions that remove a single nucleotide (Figure 3.2). 
The P9.0 helix cannot form in these constructs, and its absence does not appear to 
have negative consequences on the TES reaction (22). Since ωG binding to the 
GBS is a relatively weak interaction (52), and because it is thought that this 
interaction only occurs after the first reaction step (see previous section), it was 
expected that the formation of P10 would play a crucial role in defining and binding 
the 3’ end of the substrate to the ribozyme (for example, as the first reaction step 
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intermediate). Surprisingly, however, we found that P10 and P9.0, although 
beneficial, are not required for either step of the TES reaction.  
How is it that the 3’ exon intermediate does not readily dissociate from the 
ribozyme between the two reaction steps in this system? One possible explanation 
is that the 3’ exon is sterically constrained within the catalytic core of the ribozyme 
after the first reaction step. In other words, the 3’ exon is physically trapped within 
the ribozyme in a space for which no significant molecular interactions occur 
between the ribozyme and the 3’ reaction intermediate. Then, a conformational 
rearrangement takes place between the two reaction steps that places ωG in the 
GBS, in preparation for the second reaction step. An alternative explanation is that 
the interactions that hold the 3’ exon intermediate do not require base pairing. For 
example, it could be that the 3’ intermediate nucleotides themselves, perhaps in 
combination with the hydroxyl groups from the sugar-phosphate backbone, form 
tertiary interactions with the ribozyme. The recent report of a crystal structure of a 
group I intron with both exons trapped between the first and second splicing step 
argues against this alternative explanation (109). The reported structure indicates 
that the 3’ splice site is selected primarily by interactions with ωG as there were no 
tertiary contacts with the 3’ exon and only a single tertiary hydrogen bond between 
the intron and the P10 helix (109). A closer examination of the reported structure 
reveals that another portion of the intron could, in fact, help physically trap the 3’ 
exon in the catalytic core. 
This ability of ωG alone allowing complete TES product formation was also 
surprising because previous studies with this same ribozyme indicated it was unable 
to catalyze the complete TES reaction when excising a 20-nucleotide segment in the 
absence of P10 (32). It is likely that dissociation of the 3’ intermediate may have 
been responsible for a lack of second-step product in this previous case, as 
including a longer P9.0 interaction partially restored the function of a TES ribozyme 
(32). Apparently, this problem of intermediate dissociation is not as overwhelming 
when excising a single nucleotide. This also indicates that there are functional 
differences between TES reactions where a single base is excised relative to 
excising larger sequences. 
 45 
A mechanism for ribozyme-mediated TES product degradation  
We found that at long reaction times (relative to product formation), TES 
products dissociate and rebind the ribozyme, at which point degradation occurs via 
the 5’ cleavage reaction (i.e., ribozyme-mediated hydrolysis) at one or more new 5’ 
splice sites. We show that product cleavage does not occur through translocation of 
a bound P1 helix after product formation, as the product must first dissociate. Note, 
however, that c-C is a special case in that the substrate appears to be degraded at 
cryptic sites. Nevertheless, these results show that TES ribozymes can bind the 
products of TES reactions and essentially destroy them. This degradation 
mechanism is probably greatly aided by the conditions under which the reactions 
were run (i.e. ribozyme excess and long reaction times). Shorter reaction times 
greatly decreased cryptic degradation of products (Figure 3.6), so it is expected that 
conducting TES reactions with lower ribozyme concentrations will also help prevent 
this cryptic hydrolysis of TES products. 
Non-Watson-Crick base pairs at the 5’ splice site can help determine the binding 
register of reaction substrates  
The activation of cryptic sites during the first step of self-splicing (5’ cleavage) 
has been investigated with Tetrahymena ribozymes (63, 68, 73, 102, 103). It was 
shown that cryptic cleavage sites can become activated when the substrate helix 
shifts from the original binding register to another register without dissociation (63). 
Such a mechanism is probably occurring in our reactions where a c-C base pair 
forms at the 5’ splice site. For our cases where Watson-Crick base pairs are present 
at the 5’ splice site, cryptic sites are activated only after correct TES products form, 
the products dissociate from the ribozyme, and then bind a new ribozyme. Since 5’ 
exon translocation was not detected in these assays as a source of cryptic cleavage 
sites, it seems apparent that these TES products are binding to the recognition 
elements (RE1 and RE3) of the ribozyme, with the subsequent P1 helix docking in 
the wrong helical register. In contrast, TES products that do not contain Watson-
Crick pairs at the 5’ splice site are not degraded at cryptic sites. Apparently, non-
Watson-Crick base pairs at the 5’ splice site are acting in concert with other factors 
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to precisely determine the docking register of the P1 helix in the catalytic core of the 
ribozyme. The mechanism of this role likely includes the fact that non-Watson-Crick 
base pairs are causing a structural perturbation at the 5’ splice site, which would 
prevent the formation of a structurally uniform P1-P1ex helix (32). In the absence of 
this perturbation (which would be the case with Watson-Crick pairs at the splice 
site), the TES products bind RE1 and RE3 of the ribozyme and the subsequent P1-
P1ex helix docks within the catalytic core of the ribozyme in multiple registers, 
activating various positions within the 5’ exon for subsequent 5’ cleavage reactions. 
Such a structural perturbation would not be needed for the original TES substrates 
that have Watson-Crick base pairs, as ωG in these substrates should also be able to 
perform this role (see next section). Note that the role of non-Watson-Crick base 
pairs in defining the correct 5’ splice site must be combined with a stable base 
pairing conformation (as mentioned above) in order to allow the second reaction 
step to proceed effectively. 
Except for the case with c-C, cryptic products are created from TES products, 
indicating that the 1 h yield of TES products formed for those ribozyme-substrate 
complexes with Watson-Crick pairs at the 5’ splice site is higher than originally 
calculated. The yield of TES product created is actually the yield of TES product plus 
the yield of cryptic products. This increases the percent TES product formed to over 
50% for all Watson-Crick pairs during the 1 h reactions. Since we also see 
degradation of the TES products to 6-mers (which is the same size as the expected 
TES intermediate), some of the hydrolysis products shown in all the TES reactions 
(as the 6-mer intermediates) could have stemmed from the degradation of TES 
products. Thus, the quantified TES products presented in this work at all time points 
represent a minimum. 
ωG can help determine the binding register of reaction substrates  
Cryptic site degradation does not occur with the substrate-ribozyme 
combinations that have a Watson-Crick base pair at the 5’ splice site, yet cryptic site 
degradation occurs readily for these dissociated TES products (which rebind 
ribozyme). The only difference between the substrates and the products is the ωG 
 47 
found in the substrates. Thus, it appears that ωG can play a role in determining the 
binding register of TES reaction substrates in the catalytic core of the ribozyme. It is 
unlikely that the ω position imparts a substantial thermodynamic advantage on the 
first reaction step, so ωG is probably acting through some other mechanism. One 
possibility is that ωG, which is a single nucleotide bulge immediately 3’ to the actual 
site of 5’ cleavage, is situated ideally for disrupting the uniform sugar-phosphate 
backbone at the correct 5’ splice site in the P1 helix. This structural perturbation, 
akin to that seen above with non-Watson-Crick base pairs, although subtle, could be 
recognized and exploited by the ribozyme for directing proper binding of the P1 helix 
in the catalytic core of the ribozyme. In fact, it is likely that the ω position does not 
even have to be a guanosine to fulfill this role in the 5’ cleavage reaction, but it does 
have to be a guanosine for the second reaction step to proceed. Such a role for ωG 
in helping define the 5’ splice site has not been previously reported in any context 
with any ribozyme construct. ωG probably does not perform this role in self-splicing 
reactions, as ωG is not only part of the intron (instead of the substrate), but it is also 
not immediately adjacent to and covalently attached to the 5’ splice site. Whether the 
ribozyme has evolved to exploit this molecular recognition component, or it is 
fortuitous, is unclear. Nevertheless, in the context of the TES reaction, this 
unexpected function for ωG in aiding the fidelity of the reaction is important. 
Implications  
These results advance our knowledge of the molecular recognition involved in 
both steps of the TES reaction (and the analogous steps of self-splicing) and allow 
us to improve our design principles for developing target systems for these trans 
excision-splicing ribozymes. We are now able to target a wider range of TES 
substrates, and with more sequence specificity, particularly with regard to the 5’ 
splice site. This information will help us to further develop TES ribozymes as 
potential biochemical tools. Examples include RNA repair ribozymes (22, 30, 34), 
which would include strategies that are complementary to trans-splicing ribozymes 
(7, 21, 25), and transcript cleaving ribozymes, which would exploit the first reaction 
step, to produce transcripts ending in 3’ OH groups [which is in contrast to 
 48 
hammerhead and hairpin ribozymes, which leave 2’, 3’-cyclic phosphates (43, 48)]. 
Lastly, exploiting the TES reaction, in contrast to self-splicing or suicide inhibition, 
has allowed us to observe new and unexpected molecular recognition principles 
exploited by group I intron-mediated catalytic reactions. 
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Table 3.1:  Relative Effectiveness of Each Base in Each Position of the 5’ 
Splice Site in TES Reactions 
u 42.29 u 26.74 u 1.51 u 6.67 
c 18.29 c 30.14 c 1.27 c 1.02 
a 6.71 a 0.48 a 0.82 a 33.61 
When the 
ribozyme 
contains 
G 
g 0.87 
When the 
ribozyme 
contains 
A 
g 0.71 
When the 
ribozyme 
contains 
C 
g 44.16 
When the 
ribozyme 
contains 
U 
g 4.23 
 
U 3.58 U 21.72 U 0.60 U 3.56 
C 32.48 C 0.55 C 0.70 C 0.77 
A 1.13 A 0.63 A 33.86 A 27.48 
When the 
substrate 
contains 
g 
G 1.72 
When the 
substrate 
contains 
a 
G 11.47 
When the 
substrate 
contains  
c 
G 26.50 
When the 
substrate 
contains 
u 
G 60.43 
 
Top: Effectiveness of each ribozyme construct in TES reactions as a function 
of base identity at position 12 using each of the four 10-mer substrates that differ at 
position –1. Bottom: Effectiveness of each of the four 10-mer substrates that differ at 
position –1 in TES reactions as a function of each of the four ribozyme constructs. 
These numbers were obtained by taking the extent of TES product at 15 min of a 
particular case (for example; u-G) and dividing that by all products formed for the 
other three combinations (for example; TES, 5’ cleavage, and cryptic products for u-
A, u-C, and u-g) plus the nonproductive products of the particular case (for example; 
5’ cleavage and cryptic products for u-G). These theoretical numbers, therefore, 
represent percent product formation of one particular base pair combination in 
relation to all other products that would be produced in a 1:1:1:1 mixture of each 
ribozyme (Top of table) or substrate (Bottom of table). 
 50 
Figure 3.1.  The u-G Wobble Pair 
 
Structure showing the hydrogen bonding interactions of the u-G wobble pair 
commonly found in RNA structures. This base pairing interaction is highly conserved 
at the 5’ splice site of group I introns. The formation of this wobble pair causes a 
structural perturbation within a helical structure. The hydrogen bonding interactions 
also free two functional groups: an exocyclic amine group on the guanosine and a 
carboxyl group on the uracil. These functional groups could be recognized by 
proteins or the catalytic core of the ribozyme. 
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Figure 3.2.  Conserved Splice Site Sequences 
 
Conserved sequence elements at the 5’ and 3’ splice sites of group I introns 
and their derived ribozymes. The diagram shows the native recognition elements of 
the Pneumocystis carinii ribozyme base pairing with an RNA substrate with three 
nucleotides targeted for removal. The 5’ splice site is defined by a highly conserved 
u-G wobble pair (shown in blue). The 3’ splice site is defined by two structure 
elements (P9.0 and P10) as well as an absolutely conserved guanosine as the last 
base of the sequence targeted for excision (shown in yellow). This guanosine is 
equivalent to the ωG of the self-splicing group I intron. 
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Figure 3.3.  5’ Splice Site Test System 
 
The rP-8/4x ribozyme is in uppercase lettering, the 10-mer substrate is in 
lowercase lettering, and the single guanosine nucleotide to be excised is circled and 
in italics. The base to be excised corresponds to the ω position of self-splicing 
introns and is referred to as the substrate ω position. The ribozyme recognition 
elements RE1, RE2, and RE3 base pair with the substrate to form the P1, P9.0 and 
P10 helices, respectively. Note that the P9.0 helix does not form in this system 
because of a lack of complementary bases. The sites of catalysis for the first step (5’ 
cleavage) and the second step (exon ligation) are shown with large bold arrows. The 
P10 helix is boxed. The –1 position of the substrate (designated as y, where y = u, g, 
c, or a) and the 12 position of the ribozyme (designated as X, where X = G, C, A, or 
U) are shown in white lettering and define the native 5’ splice site. Every 
combination of the four nucleotides at X and y was analyzed. Note that the diagram 
shows only the recognition elements of the ribozyme. 
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Figure 3.4.  Results for the 5’ Splice Site During 1 Hour Reaction Times 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme for 1 h at 44 °C in 10 mM MgCl2. (Top) A representative polyacrylamide 
gel using all 16 base pair combinations at the 5’ splice site (33). Each complete 
substrate sequence and the base at ribozyme position 12 (in uppercase lettering) is 
shown above its corresponding lane. The migration position on the gel of the 10-mer 
substrates, the 9-mer products, and the 6-mer intermediates are labeled. All other 
bands represent cryptic sites. Note that there is some sequence-dependent 
migration variability between these lanes. The lanes marked “buffer” had substrate 
augacugcuc incubated as a typical reaction in the absence of ribozyme, both with (+) 
and without (-) added buffer. 
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 (Bottom) Graph of the percent of all products formed in 1 h in the TES 
reactions as a function of 5’ splice site sequence (33). The black bars on the graph 
represent 9-mer TES products, the white bars represent 6-mer 5’ cleavage products, 
and the gray bars represent all the cryptic products formed. The results are the 
average of three independent assays, and the standard deviation in all cases is less 
than 10%. Note that the order of the data in the graph does not correspond to the 
loading order of the representative gel. 
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Figure 3.5.  Time Studies Investigating the Formation of Cryptic Products 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme at 44 °C in 10 mM MgCl2. Aliquots were removed at the times listed above 
each lane. The migration position on the gel of the 10-mer substrates, the 9-mer 
products, the 6-mer intermediates, and the cryptic products are labeled. The lane 
labeled “(+) Buffer” contains a 120 min reaction in the absence of added ribozyme. 
(A) TES reaction utilizing the substrate augaccgcuc and the ribozyme rP-8/4x, which 
places a c-G pair at the 5’ splice site (33). Note that cryptic products begin to appear 
after the 15 min time point. This combination is representative of all four Watson-
Crick base pair combinations. (B) TES reaction utilizing the substrate augaccgcuc 
and the ribozyme rP-8/4x-5’C, which places a c-C pair at the 5’ splice site (33). Note 
that cryptic products begin to appear after 1 min.  
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(C) TES reaction utilizing the substrate augacugcuc and the ribozyme rP-
8/4x, which places a u-G wobble pair at the 5’ splice site (33). Note that no cryptic 
products form in this case. This combination is representative (in terms of cryptic 
product formation) of all the other base pair combinations (excluding the Watson-
Crick base pairs and the c-C pair). 
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Figure 3.6.  Results for the 5’ Splice Site During 15 Minute Reaction Times 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme for 15 min at 44 °C in 10 mM MgCl2. (Top) A representative 
polyacrylamide gel using all 16 base pair combinations at the 5’ splice site (33). 
Each complete substrate sequence and the base at ribozyme position 12 (in 
uppercase lettering) is shown above its corresponding lane. The migration position 
on the gel of the 10-mer substrates, the 9-mer products, and the 6-mer 
intermediates are labeled. All other bands represent cryptic sites. Note that there is 
some sequence-dependent migration variability between these lanes. The lanes 
marked “buffer” had substrate augacugcuc incubated as a typical reaction in the 
absence of ribozyme, both with (+) and without (-) added buffer. 
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(Bottom) Graph of the percent of all products formed in 15 min in the TES 
reactions as a function of 5’ splice site sequence (33). The black bars on the graph 
represent 9-mer TES products, the white bars represent 6-mer 5’ cleavage products, 
and the gray bars represent all the cryptic products formed. The results are the 
average of four independent assays and the standard deviation in all cases is less 
than 10%. Note that the order of the data in the graph does not correspond to the 
loading order of the representative gel. Data has been ordered according to percent 
TES product formation. 
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Figure 3.7.  Results for the 5’ Splice Site Using 3’ End Labeled Substrates 
 
Representative gel of the sequence analysis of the 5’ splice site of TES 
reactions at 15 min using 3’ end radiolabeled substrates (33). TES reactions were 
conducted the same as the reactions utilizing the 5’ radiolabeled substrates with 1.3 
nM radiolabeled substrate and 166 nM ribozyme at 44 °C in 10 mM MgCl2. Each 
complete substrate sequence and the base at ribozyme position 12 (in uppercase 
lettering) is shown above its corresponding lane. Note that the final c on each 
substrate is the radiolabeled c added by the 3’ radiolabeling procedure. The 
migration position of the 11-mer substrates and the 10-mer products are labeled. 
The lanes marked “buffer” had substrate augacugcucc incubated as a typical 
reaction in the absence of ribozyme, both with (+) and without (-) added buffer.  The 
lane marked “(+) control” is a TES reaction using 5’ radiolabeled substrate and the 
conserved u-G wobble pair at the 5’ splice site run under the same conditions as the 
3’ radiolabeled substrates.  
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Figure 3.8.  Time Studies to Identify the Source of the Cryptic Products  
 
Time-dependent polyacrylamide gel of TES reactions utilizing 9-mer TES 
product (left) and 6-mer intermediate (right) as reaction substrates (33). Reactions 
were conducted with 1.3 nM radiolabeled substrate and 166 nM ribozyme at 44 °C in 
10 mM MgCl2. The ribozyme used in each case was rP-8/4x-5’A, which when paired 
with the substrate will create a u-A base pair at the 5’ splice site. Aliquots were 
removed at the times listed above each lane. The migration positions on the gel of 
the 9-mer and 6-mer starting material are labeled. Unlabeled bands are cryptic 
products. The lanes marked “buffer” were incubated as a typical reaction for 120 min 
in the absence of ribozyme, both with (+) and without (-) added buffer. Note that 
cryptic products only occur when using the 9-mer TES product. 
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Figure 3.9.  Competition Studies Investigating Product Dissociation and 
Rebinding 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme at 44 °C in 10 mM MgCl2. The ribozyme used in each case was rP-8/4x-
5’A, which when paired with the substrate augacugcuc will create a u-A base pair at 
the 5’ splice site. After the reaction proceeded for 5 min, 1.3 μM of the unlabeled 
TES product (1000-fold excess over substrate) was added to one of the reactions. 
Aliquots were removed starting 10 min later (15 min after start of the reaction). 
Shown are graphs comparing reactions in the absence (left) and presence (right) of 
this unlabeled competitor (33). TES products are represented by black circles, 6-mer 
hydrolysis products by white circles, and all cryptic products by white triangles. The 
addition of competitor does reduce the amount of TES product formed because not 
all the labeled substrate has had a chance to bind the ribozyme prior to this addition. 
Of the labeled substrate that does bind, however, the addition of competitor 
eliminates the formation of cryptic products. This indicates the products dissociate 
and, in the presence of excess unlabeled product, are unable to rebind ribozymes 
for cryptic cleavage. 
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Figure 3.10.  Results for the 3’ Splice Site for 1 Hour Reaction Times 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme for 1 h at 44 °C in 10 mM MgCl2. (Top) Diagram of the model TES reaction 
used (33). The four substrates utilized were 10-mers (shown in lowercase lettering), 
where x is one of each of the four nucleotides. Note that x represents the substrate 
position analogous to the ω position of self-splicing introns. The recognition 
elements from ribozyme rP-8/4x are shown in uppercase lettering. 
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(Bottom) Graph of the percent of all products formed in the TES reactions as 
a function of 3’ splice site sequence (33). The black bars represent 9-mer TES 
products and the white bars represent 6-mer 5’ cleavage products. The results are 
the average of two independent assays and the standard deviation in all cases is 
less than 10%. Notice that only ωG produces TES product. 
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Figure 3.11.  Results for Reactions Where no P10 Formation Is Possible 
 
Reactions were conducted with 1.3 nM radiolabeled substrate and 166 nM 
ribozyme for 1 h at 44 °C at the MgCl2 concentrations listed on the graph. (Top) 
Diagram of the model TES reaction used (33). The substrate 10-mer is shown in 
lowercase lettering and the recognition elements of the ribozyme are shown in 
uppercase lettering. In this system, P10 formation is not possible. (Bottom) Graph of 
the percent of all products formed in the TES reactions as a function of MgCl2 
concentration. The black bars represent 9-mer TES products and the white bars 
represent 6-mer 5’ cleavage products. The results are the average of two 
independent assays, and the standard deviation in all cases is less than 10%. 
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CHAPTER 4 - IN VIVO EXCISION OF A SINGLE TARGETED NUCLEOTIDE 
FROM AN RNA TRANSCRIPT BY A TRANS EXCISION-SPLICING RIBOZYME 
 
Proposed Project 
To date, the studies on TES ribozymes have been performed in vitro (22, 32, 
33). While these studies have shown the potential of TES ribozymes as viable 
biochemical tools in the test tube, the usefulness of these ribozymes will be 
enhanced by demonstrating in vivo reactivity. These TES ribozymes could be used 
as biochemical tools for the sequence specific modification of RNA transcripts in 
vivo. The ability of TES ribozymes to specifically remove sequences from within 
RNAs has potential therapeutic value in that they can be used to remove mutations 
associated with diseases at the RNA level. These therapeutic applications depend 
on demonstrated in vivo reactivity. Other group I intron-derived ribozymes have 
demonstrated reactivity in non-native cellular contexts, including therapeutically 
relevant systems (7, 10, 12-15, 19, 21, 23, 25, 26, 28, 29), so it is feasible that the P. 
carinii ribozyme can catalyze the TES reaction in vivo. However, there are 
differences between the TES ribozyme and other group I intron-derived ribozymes 
that may result in a lack of activity in a non-native cellular setting. Thus, it is vitally 
important to determine if the TES ribozyme is active in vivo. 
To this end, I have designed a test system to assess the ability of the P. 
carinii ribozyme to catalyze the TES reaction in a non-native cellular environment, 
specifically Escherichia coli. Green fluorescent protein (GFP) was chosen as the 
target for this system because it can be expressed in many different cellular 
environments (85, 88) and simple changes to the coding region can completely 
destroy its fluorescent properties (90, 130). A single base insertion mutation was 
engineered into the GFP gene, which causes a frameshift in the coding region of the 
mRNA and produces a non-fluorescent protein product. The P. carinii ribozyme was 
reengineered to target this mutation, so a successful TES reaction will reestablish 
the reading frame of the protein and will produce a fluorescing protein (Figure 4.1). A 
single base was targeted for excision because this represents the simplest TES 
target system and limits the number of recognition elements utilized by the ribozyme 
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to two. Cell cultures were monitored for an increase in GFP fluorescence upon 
induced ribozyme transcription to determine ribozyme reactivity in vivo. These 
studies were undertaken to demonstrate the ability of the TES ribozyme in vivo and 
to establish the groundwork for future studies of these ribozymes in more complex, 
and therapeutically relevant, systems. 
Materials and Methods 
Oligonucleotide synthesis and preparation 
DNA oligonucleotides for site-directed mutagenesis were purchased from 
Integrated DNA Technologies (Coralville, IA). Oligonucleotides for the insertion of 
the T7 terminator sequence into the P-8/4x ribozyme precursor plasmid (P3X) were 
also purchased from Integrated DNA Technologies and were 5’ phosphorylated and 
purified via polyacrylamide gel electrophoresis (PAGE) by the company. 
Plasmid construction 
The P. carinii ribozyme precursor plasmid, P-8/4x, was constructed as 
previously described (11). Note the P-8/4x plasmid will be referred to as the P3X 
plasmid in this chapter. To stop transcription of the ribozyme in vivo, a T7 terminator 
sequence (131) was inserted immediately 3’ to the ribozyme sequence (Figure 4.2). 
This insertion was made using the XbaI and HindIII restriction enzyme sites present 
in the P3X plasmid (Figure 4.3). The P3X plasmid was digested with HindIII and the 
linear plasmid was purified from the reaction mixture using a QIAquick PCR 
Purification kit (QIAGEN; Valencia, CA). The linear plasmid was then digested with 
XbaI and the double-cut plasmid was purified from the reaction mixture using a 
QIAquick PCR Purification kit. The following oligonucleotides containing the T7 
terminator sequence were ligated into the double cut P3X plasmid to create 
P3X+T7T:  
5’CTAGATAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGA
3’ and 
5’AGCTTCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAT
3’. The ligation reaction consisted of 300 ng double-cut P3X plasmid, ~245 ng 
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double-stranded T7 terminator insert, 30 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 10 
mM dithiothreitol (DTT), 1 mM ATP, and 3 U T4 DNA ligase (Promega; Madison, WI) 
in a 10-μL reaction volume. All components, except the ligase, were mixed and 
incubated at greater than 80 ºC for 1 minute. The mixture was cooled to room 
temperature and then the ligase was added. The ligation reaction proceeded at room 
temperature overnight. A 3-μL aliquot of the overnight ligation reaction was then 
used to transform Escherichia coli DH5α competent cells (Invitrogen; Carlsbad, CA). 
The resulting plasmid (P3X+T7T) was purified using a QIAprep Spin Miniprep kit 
(QIAGEN) and sequenced for confirmation (ACGT, Inc.; Northbrook, IL). 
Two unique restriction enzyme sites, BglII and SphI, were engineered into the 
newly created P3X+T7T plasmid to allow for the excision of the ribozyme construct 
(Figure 4.3). The plasmid, P3X+T7TBS, was created by two successive rounds of 
site-directed mutagenesis. The following primer pair was used to create a BglII 
restriction site upstream of the T7 promoter:  
5’GGAAACAGATCTGACATGATTACGAATTTGG3’ and 
5’CCAAATTCGTAATCATGTCAGATCTGTTTCC3’. A SphI restriction site was 
created downstream of the T7 terminator with the following primer pair:  
5’GCTTACTAGTGATGCATGCTCTATAGTGTCACC3’ and 
5’GGTGACACTATAGAGCATGCATCACTAGTAAGC3’. The created restriction sites 
are underlined. The site-directed mutagenesis reactions were conducted as 
previously described (22), with the changes that follow. The reaction mixtures were 
subjected to denaturation at 95 ºC for 30 s, followed by 15 temperature cycles of 95 
ºC for 30 s, 55 ºC for 2 min, and 68 ºC for 6 min. The parental plasmids were 
digested with 20 units of DpnI (New England Biolabs; Beverly, MA) in 4.2 μL of 
manufacturer’s buffer for at least 1 h at 37 ºC. A 3-μL aliquot of this digest was then 
used to transform E. coli DH5α competent cells. The resultant plasmids were purified 
using a QIAprep Spin Miniprep kit and were sequenced for confirmation (Davis 
Sequencing; Davis, CA). 
The plasmid containing the GFP target, pQBI T7-GFP, was purchased from 
QBIOGENE (Carlsbad, CA). The base plasmid for testing, pQBI GFP + P3X, was 
created by inserting the ribozyme construct into the pQBI T7-GFP plasmid using the 
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BglII and the SphI restriction sites present in the pQBI T7-GFP plasmid (Figure 4.3). 
The pQBI T7-GFP plasmid was prepared by first digesting with SphI. The linear 
plasmid was purified from the reaction mixture using a QIAquick PCR Purification kit. 
The linear plasmid was then digested with BglII. The double-cut plasmid was purified 
on a 1.2% agarose gel and the plasmid band was excised. The plasmid was 
extracted from the gel matrix using a QIAquick Gel Extraction kit (QIAGEN). The gel-
purified plasmid was then ethanol precipitated twice prior to ligation. The ribozyme 
construct was isolated from the P3X+T7TBS plasmid by the following process. The 
P3X+T7TBS plasmid was first digested with SphI and the linear plasmid was purified 
from the reaction mixture using a QIAquick PCR Purification kit. The linear plasmid 
was then digested with BglII and the resulting bands were purified on a 1.2% 
agarose gel. The ribozyme construct band was excised and extracted from the gel 
matrix using a QIAquick Gel Extraction kit. The gel-purified product was ethanol 
precipitated twice prior to ligation. The ligation reaction consisted of ~50 ng double-
cut pQBI T7-GFP plasmid, ~125 ng ribozyme construct, 30 mM Tris-HCl (pH 7.8), 10 
mM MgCl2, 10 mM DTT, 1 mM ATP, and 3 U T4 DNA ligase (Promega) in a 13-μL 
reaction volume. All components, except the ligase, were mixed and incubated at 
greater than 90 ºC for 1 minute. The mixture was cooled to room temperature and 
then the ligase was added. The ligation reaction proceeded at room temperature 
overnight. A 3-μL aliquot of the overnight ligation reaction was then used to 
transform E. coli DH5α competent cells. The resulting plasmid (pQBI GFP + P3X) 
was purified using a QIAprep Spin Miniprep kit and sequenced for confirmation 
(Davis Sequencing). 
Test plasmids were generated via site-directed mutagenesis of the base 
plasmid pQBI GFP + P3X. The following primers were used to modify the GFP gene 
to contain a single base insertion mutation to destroy GFP fluorescence (Mut GFP):  
5’GCAGATTGTGTGGACAAGGTAATGGTTGTCTGG3’ and 
5’CCAGACAACCATTACCTTGTCCACACAATCTGC3’. The underlined base 
represents the insertion mutation. The expected product from a successful TES 
reaction (Corr GFP) was created with the following primers:  
5’GCAGATTGTGTGGAAAGGTAATGGTTGTCTGG3’ and 
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5’CCAGACAACCATTACCTTTCCACACAATCTGC3’. The underlined base 
represents the silent mutation expected from removal of the targeted guanosine by 
the TES ribozyme. These mutations alter codon 201 of the GFP gene. Site-directed 
mutagenesis was performed as described above, with the following modifications. In 
various reactions, the annealing temperature was lowered to 50 ºC, the elongation 
time was increased from 6 min to 8 min to account for the larger plasmid, and/or the 
number of temperature cycles was increased to 18 cycles. Resulting plasmids were 
purified as above and sequenced for confirmation (Davis Sequencing). 
The ribozyme portion of the test plasmid was modified in the following ways 
using site-directed mutagenesis. First, two of the three recognition elements of the 
ribozyme (RE1 and RE3) were modified to recognize the GFP target by two 
successive rounds of site-directed mutagenesis. A third recognition element (RE2) is 
not utilized or required in TES reactions excising a single base (22, 33), so it was not 
modified. The primers for the first round of sequence changes were:  
5’CGACTCACTATAGAGGGGGTAGAAAGCGGC3’ and 
5’GCCGCTTTCTACCCCCTCTATAGTGAGTCG3’. The second round of changes 
was made with the following primer pair:  
5’CGACTCACTATAGGAGAGGTAGAAAGCGGC3’ and 
5’GCCGCTTTCTACCTCTCCTATAGTGAGTCG3’. The length of RE3 was increased 
to 5 bases using the following primers:  
5’CGACTCACTATAGTGGAGAGGTAGAAAGCGGC3’ and 
5’GCCGCTTTCTACCTCTCCACTATAGTGAGTCG3’. An RE3 containing 7 bases 
was created using the following primer pair:  
5’CGACTCACTATAGTGTGGAGAGGTAGAAAGCGGC3’ and 
5’GCCGCTTTCTACCTCTCCACACTATAGTGAGTCG3’. The underlined bases 
represent the bases used to increase the length of the RE3 region. A mutant form of 
the ribozyme was created by deleting four bases from the Guanosine Binding Site 
(GBS) using the following primers:  5’GGATGCAGTTCACTAGATGGCAGTGG3’ and 
5’CCACTGCCATCTAGTGAACTGCATCC3’. This removes bases 250-253 from the 
ribozyme sequence (11). Site-directed mutagenesis reactions were performed as 
above, with annealing temperatures of 50 ºC or 55 ºC, elongation times of 8 min, 
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and 18 temperature cycles. Resulting plasmids were sequenced to confirm the 
changes (Davis Sequencing). 
Preparing competent JM109(DE3) 
In vivo testing of the TES ribozyme was conducted in E. coli strain 
JM109(DE3). This strain was chosen because it contains the gene encoding T7 
RNA polymerase under the control of an inducible promoter. Competent 
JM109(DE3) cells were prepared using the rubidium chloride protocol reported by 
Promega (132). JM109(DE3) cells from a glycerol stock (Promega) were streaked 
on an M-9 minimal agar plate containing 1mM thiamine-HCl and the plate was 
incubated at 37 ºC overnight. An overnight culture of JM109(DE3) was created using 
5 mL of room temperature LB media and colonies from the streaked JM109(DE3) 
plate. The culture was then incubated at 37 ºC with shaking at 225 rpm overnight. 
The next day, an aliquot of the overnight culture of JM109(DE3) was used to 
inoculate LB media containing 20 mM MgSO4 to give a 1:100 dilution. The dilution 
culture was grown at 37 ºC with shaking at 225 rpm until the A600 (absorbance of the 
bulk culture at 600 nm) reached 0.4–0.6. Cells were pelleted by centrifuging at 4,500 
x g for 5 min at 4 ºC. The supernant was removed from the pellets and the cell 
pellets were resuspended in 0.4 volume (of the original culture) of ice cold TFB1, 
which consists of 30 mM potassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM 
RbCl and 15% glycerol at pH 5.8. The resuspended cells were incubated on ice for 5 
min and the cells were then pelleted by centrifuging at 4,500 x g for 5 min at 4 ºC. 
The supernant was removed and the cells were resuspended in 1/25 volume (of the 
original culture volume) of ice cold TFB2, which consists of 10 mM PIPES (pH 6.5), 
75 mM CaCl2, 10 mM RbCl, and 15% glycerol at pH 6.5. The resuspended cells 
were then incubated on ice for 1 h. 
Transformation of competent JM109(DE3) 
Following the 1 h incubation on ice, the competent cells were transformed 
with the test plasmids using a modified version of the procedure outlined by 
Promega (132). 100 μL of competent cells was used in each transformation reaction. 
Approximately 10 ng of test plasmid was swirled into the competent cells and the 
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tubes were incubated for 30 min on ice. The cells were then heat shocked to allow 
transformation by heating the tubes at 44 ºC for 50 sec and placing the tubes 
immediately back on ice for 2 min. 1.5 mL of room temperature LB media was then 
added to each tube and the tubes were incubated at 37 ºC with shaking at 225 rpm 
for 45 min. After incubation, 200 µL of each transformation reaction was plated on 
LB plates containing ampicillin and the plates were incubated at 37 ºC overnight. 
In vivo TES reactions 
The colonies resulting from transformation of the competent JM109(DE3) 
cells were used for in vivo testing of the TES ribozymes. The colonies were picked 
and used to inoculate 3 mL of LB media containing ampicillin. The cultures were 
incubated at 37 ºC with shaking at 225 rpm overnight. The following day, the 
overnight cultures were used to inoculate fresh LB media without antibiotic to create 
1:20 dilution cultures. Each 1:20 dilution culture consisted of 8 mL of LB media and 
400 μL of overnight culture. The dilution cultures were incubated at 37 ºC with 
shaking at 225 rpm for 3 h to allow growth to reach log phase (A600 > 0.4). After 3 h, 
aliquots were removed from each culture for cell density analysis (500 μL) and 
fluorescence analysis (1 mL). The rest of the dilution culture was then subdivided. 
The inducer, isopropylthiogalactoside (IPTG), was added to one of the cultures to a 
final concentration of ~1.3 mM, while the other culture served as a non-induced 
control. IPTG is a galactose mimic which induces, or activates, the lac promoter that 
controls production of T7 RNA polymerase in JM109(DE3). IPTG cannot be 
hydrolyzed by the cell, so the concentration of IPTG stays constant throughout the 
course of the experiment. Cultures were incubated at 37 ºC with shaking at 225 rpm 
for 5 h. After 5 h, aliquots were removed for cell density analysis (500 μL), GFP 
fluorescence analysis (1 mL) and for select cultures, total RNA isolation (1 mL). 
Analysis 
Cell density was determined by measuring the absorbance of the culture at 
600 nm (A600). For GFP fluorescence analysis, the culture aliquots were centrifuged 
at 6,000 x g for 12 min at 4 ºC to pellet the cells. The media was removed and the 
cell pellets were resuspended in 300 μL of phosphate buffered saline (PBS) at pH 
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7.4. The LB media used in these studies has fluorescent properties that could 
interfere with GFP fluorescence detection, so the cells were resuspended in PBS, 
which is not fluorescent. The resuspended pellets were then loaded into a 
FluoroNuncTM MaxiSorpTM 96-well plate (Nalge Nunc International; Rochester, NY). 
GFP fluorescence was measured in a CytoFluor (PerSeptive Biosystems; 
Framingham, MA), using a 485 ± 20 nm filter for excitation and a 508 ± 20 nm filter 
for emission, as the excitation wavelength for this form of GFP is 474 nm and the 
emission wavelength is 509 nm. Use of the CytoFluor was kindly provided by the lab 
of Dr. Sylvia Daunert (University of Kentucky). The raw fluorescence measurements 
are adjusted to correct for differences in cell culture growth by dividing the raw 
fluorescence values by the A600 readings. These adjusted fluorescence values were 
then normalized to the non-induced values to correct for “leaky” T7 RNA polymerase 
activity. This correction was made by subtracting the adjusted fluorescence for the 
non-induced culture from the adjusted fluorescence for the induced culture. These 
adjusted values are the normalized fluorescence values reported in the graphs. Note 
that omitting the corrections for differences in cell density does not significantly affect 
the trends obtained (data not shown). Error limits for the estimated percentages of 
RNA repair were calculated as for multiplicative expressions (133). 
Total RNA isolation 
Total RNA was isolated from 1 mL aliquots from designated cultures using the 
Ambion RiboPureTM-Bacteria Kit (Ambion, Inc.; Austin, TX). Isolated RNA was 
treated with RQ1 RNase-Free DNase (Promega) to completely remove the DNA 
prior to RT-PCR. RNA was isolated from the DNase reaction mixture by acid phenol 
(pH 4.3) extraction, followed by phenol/chloroform extraction and ethanol 
precipitation. DNase treatment was repeated as necessary to ensure the DNA had 
been removed from the samples (as confirmed by PCR). 
RT-PCR reactions 
The GFP transcripts were amplified from the total RNA by RT-PCR using the 
following primers:  5’GTTGTACAGTTCATCCATGCC3’ and 
5’GGAGAAGAACTCTTCACTGG3’. RT-PCR reactions were performed using the 
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Access RT-PCR System (Promega) and consisted of 50 μL reactions containing ~1 
μg total RNA, 1 mM MgSO4, 45 pmol of each primer, 0.2 mM dNTPs, 5 U AMV 
Reverse Transcriptase, and 5 U Tfl DNA Polymerase in the provided reaction buffer. 
PCR reactions were performed as a control to ensure the DNA had been removed 
from the samples. The reactions were subjected to 45 ºC for 45 minutes for first 
strand cDNA synthesis, followed by 2 minutes at 94 ºC to inactivate the AMV 
Reverse Transcriptase. The reactions then underwent 40 temperature cycles 
consisting of 94 ºC for 30 s, 54 ºC for 1 min, and 68 ºC for 2 min. After cycling was 
complete, the reactions underwent a final extension cycle at 68 ºC for 10 min. The 
RT-PCR products were separated on a 2% agarose gel and the GFP band was 
excised from the gel. The band was extracted from the gel matrix using a QIAquick 
Gel Extraction kit. The gel-purified products were ethanol precipitated twice prior to 
use in ligation reactions. 
Assay for corrected transcripts 
The GFP RT-PCR products were ligated into the pDrive cloning vector using 
the QIAGEN PCR Cloning kit (QIAGEN). Ligation reactions consisted of 50 ng 
pDrive Cloning Vector, 200 ng of RT-PCR product, 1 μL 50% polyethylene glycol 
(PEG; 5% final w/v), and 2X Ligation Master Mix (provided with the kit) in a final 
volume of 10 μL. Ligations proceeded for 1.5 h at 4 ºC. Immediately after ligation 
was complete, a 3-μL aliquot of the ligation reaction was used to transform E. coli 
DH5α competent cells. Transformations were plated on LB media plates containing 
kanamycin and the plates were incubated at 37 ºC overnight. The following day, the 
plates were placed at 4 ºC for at least 4 h to enhance GFP fluorescence for 
visualization. After incubation at 4 ºC, the plates were exposed to UV light and 
colonies showing GFP fluorescence were isolated. The isolated colonies were used 
to inoculate LB media containing kanamycin and the cultures were incubated at 37 
ºC with shaking at 225 rpm overnight. The following day, the resulting plasmids were 
isolated from the cultures using a QIAprep Spin Miniprep kit and sequenced for 
identification (Davis Sequencing). 
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System Design 
Design of the in vivo test system 
In order to evaluate the activity of the TES ribozyme in vivo, a reporter gene 
with activity that could be easily measured was chosen as the target. Green 
fluorescent protein (GFP) was a good candidate because it has been express in 
many cell types and it does not require species-specific cofactors to fluoresce (85, 
88). Also, simple changes to the coding region completely eliminate fluorescence 
(90, 130). Thus, creating a simple insertion mutation in the coding region of GFP will 
destroy fluorescence and the TES ribozyme can be used to remove the insertion 
and reestablish fluorescence. 
The design of the in vivo TES test system was based on previous work 
involving the trans-splicing ribozyme in E. coli (7, 15), as well as design principles 
garnered through studies of the TES ribozyme in vitro (22, 32). The simplest TES 
reaction system involves the removal of a single nucleotide from a substrate. This 
single nucleotide is equivalent to the ω position in the self-splicing reaction (60, 104-
109, 134). We had previously shown that the only single nucleotide that can by 
excised by the TES ribozyme is a guanosine (33), so the nucleotide targeted for 
removal is a guanosine. A GFP test system was designed in which a single base 
insertion mutation was created in the coding region of GFP (Figure 4.1). This 
mutation causes a deleterious shift in the reading frame of the transcribed RNA, 
which alters the amino acid sequence of the resultant protein product, resulting in a 
loss of fluorescence. To create this mutation, a uridine was inserted 5’ to a 
guanosine in the RNA transcript (Figure 4.1). In the context of the TES reaction, this 
uridine will serve to define the 5’ splice site by forming the highly conserved u-G 
wobble pair with a guanosine in the ribozyme (11, 22, 33, 59, 68, 73, 102, 103). 
Insertion of a uridine ensures that the ribozyme will target the mutant form of GFP 
and not the normal form, as the formation of a u-G wobble pair will be favored over a 
g-G pair at the 5’ splice site, although 5’ cleavage is still possible (33). The 
guanosine following the inserted uridine represents ωG and it is the base targeted 
for excision (Figure 4.4). After a successful TES reaction, the inserted uridine 
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replaces the guanosine in the coding region. Thus, the site for insertion was limited 
to those codons where replacement of guanosine by uridine results in a silent 
mutation and the amino acid sequence of the normal and corrected protein are the 
same. Codon 201, which codes for leucine, fits these criteria and, based on RNA 
structure prediction estimates, was accessible in the transcript. Thus, a successful 
TES reaction will put the GFP transcript back in frame, will produce the correct 
amino acids, and will restore fluorescence to the resultant protein product, while 
creating a G-to-U transversion in the RNA sequence (Figure 4.1). This G-to-U 
transversion can later be identified via sequencing of isolated transcripts. 
Changes to modify the ribozyme were kept to a minimum for these initial in 
vivo studies. A T7 terminator sequence (131) was added to the 3’ end of the 
ribozyme sequence to stop transcription of the ribozyme in vivo. Addition of this 
terminator increases the length of the ribozyme by ~50 nucleotides. This T7 
terminator sequence (shown in red in Figure 4.2), slows down the T7 RNA 
polymerase (via the formation a hairpin structure) and promotes dissociation of the 
polymerase from the transcript (via a string of uridines), thus stopping transcription 
(131). Two of the three recognition elements used by the ribozyme for target 
identification were modified to target the GFP transcript at the site of the insertion 
mutation (Figure 4.4). The third recognition element, RE2, is not utilized in TES 
reactions involving the removal of a single nucleotide, so it was not modified. In all 
the in vivo test systems, the length of RE1 was maintained at the native length of 6 
nucleotides. Previous work on the TES ribozyme indicated that increasing the length 
of RE3 can be beneficial to the reaction (32), while work with the trans-splicing 
ribozyme showed a requirement for P10 and increased 3’ exon interactions for in 
vivo activity (14, 15, 19, 21, 23, 25-29), so ribozymes were tested with RE3 lengths 
of 3 nucleotides (native length), 5 nucleotides, and 7 nucleotides. The choice of 
increasing RE3 to 5 nucleotides and 7 nucleotides was made primarily on the 
sequence of the target transcript. T7 RNA polymerase prefers that the initiation base 
for transcription be a guanosine (135, 136). As the first nucleotide of the ribozyme 
that is transcribed is the 5’ nucleotide of RE3, this base must be a guanosine. This 
also means that the target must contain a cytidine (the base pairing partner for 
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guanosine), so the GFP sequence was analyzed for downstream cytidines to define 
the end of the P10 helix. Increasing the helix length to 5 nucleotides and 7 
nucleotides utilizes the next two cytidines in the GFP sequence (Figure 4.1). As a 
control for ribozyme activity, mutant ribozyme constructs were constructed by 
deleting four nucleotides from the guanosine binding site of the ribozyme (enclosed 
in the gray oval in Figure 4.2). This mutation completely inactivates the ribozyme 
when tested in vitro (data not shown). 
In designing a plasmid for testing, I chose to utilize a single plasmid system to 
introduce the ribozyme and the target into the cells. A single plasmid ensures that 
both components for the reaction (substrate and ribozyme) are efficiently 
transformed into the cells for testing. 
Experimental design for the assay for corrected transcripts 
Selectively isolating the corrected transcripts from a mixture of mutant and 
corrected transcripts presents unique challenges. The TES reaction removes a 
targeted sequence from within an RNA, so the 5’ and 3’ ends of the transcript are 
the same in the mutant and corrected forms. Moreover, in this simple system, the 
difference between the mutant GFP transcript and the corrected GFP transcript is a 
single nucleotide. Thus, the corrected transcript cannot trivially be selectively 
amplified by RT-PCR. Therefore, an assay was designed to isolate and analyze the 
pool of transcripts after the reaction for those that are corrected and thus produce 
fluorescent protein.  
In this assay, a pool of GFP transcripts is amplified from total RNA isolated 
from the in vivo reactions (Figure 4.5). The primers used to amplify the transcripts 
are targeted to the ends of the GFP transcript, thus amplifying the entire GFP coding 
region. The pool of GFP RT-PCR products will represent the pool of GFP transcripts, 
with mutant GFP and corrected GFP products being present. The resulting GFP RT-
PCR products are purified on an agarose gel and the mixture of the RT-PCR 
products are ligated into the pDrive cloning vector. This vector was chosen for a few 
reasons. The pDrive cloning vector is pre-cut and contains U overhangs, which allow 
for cloning of the RT-PCR products, which have A overhangs. Thus, one RT-PCR 
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product ligates into one plasmid. The placement of the overhangs in the pDrive 
vector allows for the insertion of the GFP RT-PCR product in frame with the lac Z 
gene present in the plasmid, thus creating a fusion between the lac Z and the GFP. 
Expression of this fusion protein allows for the identification of the GFP product. 
Cloning of the ligation products into DH5α cells leads to the introduction of one 
plasmid per transformed cell. When the transformations are plated on agar plates, 
each transformed cell produces a colony. Each colony on the plate represents an 
individual ligation event and thus a single RT-PCR product that resulted from 
amplification of a GFP transcript (either mutant or corrected). As each colony will 
only contain one plasmid, the lac Z-GFP fusion protein produced will be the same in 
all the cells that make up the colony. Those colonies containing the corrected GFP 
products (with the insertion mutation removed) will produce fluorescent GFP at a 
high level, which can be visualized on the plate. On the other hand, those colonies 
containing the mutant GFP products will produce non-fluorescent protein products 
and will not fluoresce when exposed to UV light. This assay allows for the screening 
of numerous RT-PCR products and selective isolation of corrected GFP products. 
Results 
The expected product form of GFP is fluorescent 
Prior to testing the targeted ribozymes with the mutant GFP target, I tested to 
see that the mutation introduced into the GFP gene abolishes fluorescence. I also 
tested to see if the expected product form of GFP (with the G-to-U transversion) 
fluoresces. As seen in Figure 4.6, introducing the insertion mutation into the GFP 
gene abolishes GFP fluorescence. The expected product fluoresces, although at a 
level somewhat below that for the normal form of GFP, indicating the G-to-U 
transversion is not largely disruptive to the translation of the GFP protein. These 
tests were conducted using the different forms of GFP in the same plasmid as the 
non-specific ribozyme (rP3X), so the results are obtained in the presence of active 
(although non-targeted) ribozyme. The reported values are the result of 4 
independent assays and the standard deviations are below 10%. 
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The TES ribozyme is active in vivo 
The ribozymes engineered to target the mutation in GFP were tested for in 
vivo activity by pairing the ribozymes with the mutant form of GFP (Mut GFP). 
Targeted ribozymes (GFP rP3X) were tested with RE3 lengths of 3 nucleotides, 5 
nucleotides and 7 nucleotides. Increasing the length of RE3 increases the interaction 
between the ribozyme and the 3’ exon of the substrate. These increased base 
pairing interactions help prevent 3’ exon dissociation prior to the second reaction 
step and can improve TES product formation in vitro (32). The native form of the 
ribozyme (rP3X) served as a non-GFP-targeted control for ribozyme activity, while 
inactive forms of the ribozymes (containing a 4-nucleotide deletion in the guanosine 
binding site) were used as negative controls. As seen in Figure 4.7, increasing the 
length of RE3 to 5 nucleotides for the targeted ribozyme (GFP rP3X RE3=5) 
significantly increases the fluorescence over the inactive and the non-specific 
ribozyme controls, indicating TES reactivity. The reported values are the result of 4 
independent assays and the standard deviations are below 10%. Note the level of 
fluorescence for the negative controls is not zero due to a low level of inherent 
fluorescence in the samples. I obtained an estimate of TES reactivity by comparing 
the data from the constructs with mutant GFP (Figure 4.7) and the same ribozyme 
constructs with the expected product form of GFP. For the expected product, 
normalized fluorescence values of 16265.99 ± 388.75 (ribozyme with an RE3=3), 
3105.83 ± 1940.59 (ribozyme with an RE3=5), and 5971.97 ± 2272.05 (ribozyme 
with an RE3=7) were obtained from at least 3 independent tests. Note the large 
standard deviations result from greater variability in reactions conducted in vivo 
when the RE3 length is increased from the native length of 3 nucleotides in 
constructs containing the expected product form of GFP. The estimated percentage 
of RNA repair was low for the targeted ribozymes with RE3 lengths of 3 nucleotides 
(1.1 ± 0.1%) and 7 nucleotides (3 ± 1%), while utilizing a targeted ribozyme with an 
RE3 length of 5 nucleotides increased the estimated percentage of repair to 12 ± 
8%. 
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The targeted guanosine is removed from the corrected transcripts 
Total RNA was isolated from reactions involving 3 different constructs: the 
mutant GFP paired with the targeted ribozyme containing an RE3=5 (the repair 
construct that showed the greatest increase in GFP fluorescence), the mutant GFP 
paired with the inactive targeted ribozyme with an RE3=5 (a negative control), and 
the expected product form of GFP paired with the targeted ribozyme with an RE3=5 
(a positive control to assess the insertion efficiency). The total RNA was subjected to 
RT-PCR to isolate the GFP transcript and the resulting RT-PCR products were 
ligated into a cloning vector and were assayed for their ability to produce fluorescent 
protein (Figure 4.5). In the screening assays, twelve fluorescent colonies (out of 
~2000 screened colonies) were obtained from products from 2 independent in vivo 
tests with the active repair construct, indicating the presence of corrected transcripts. 
Assays involving products from three independent in vivo tests with the mutant 
ribozyme construct produced no fluorescent colonies in ~2000 screened colonies, 
indicating that no TES reaction had occurred. The twelve fluorescent colonies from 
the active repair construct, one non-fluorescent colony from the active repair 
construct and eighteen non-fluorescent colonies from the negative control construct 
were isolated and the resulting plasmids were sequenced. All twelve sequences 
from the fluorescent colonies showed the removal of the targeted guanosine, 
resulting in the G-to-U transversion in the corrected transcript (Figure 4.8). If the cell 
randomly fixed the transcript and produced fluorescent protein, the loss of a uridine 
would be anticipated to be as likely as the loss of a guanosine. As this loss of a 
uridine was not observed, the fluorescent protein was produced as a result of a 
successful TES reaction. There was also no evidence of a deletion that could serve 
as a compensatory mutation to restore fluorescence. The non-fluorescent colonies 
were confirmed to contain the mutant GFP transcript, which still contains the 
targeted guanosine (Figure 4.8). Thus the removal of the targeted guanosine was 
TES ribozyme-mediated (without being deleterious to the cell) and dependent on 
active ribozyme. Based on this method, ~1.2% of the mutant transcripts are 
corrected by the TES ribozyme. 
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Discussion 
The arsenal of molecular-based RNA tools is rapidly growing; however, the 
majority of these tools have focused on the destruction of the RNA message rather 
than the modification of the message (24, 37, 39). Destroying the RNA message is 
useful for studying the effects of shutting off genes and can be useful in therapeutic 
applications to prevent the production of mutant proteins that lead to disease. On the 
other hand, modifying the RNA message can restore the function to the transcript, 
thus reducing mutant protein and producing normal protein. With this in mind, this 
work reports the development of a catalytic RNA that can sequence specifically 
target a single nucleotide within a cellular transcript in vivo and excise that targeted 
nucleotide from the transcript, with little or no apparent toxicity to the cell (30). 
Combined with the ease of adaptability, this provides for a wide variety of new in 
vivo experimental strategies. 
As TES ribozymes recognize their targets initially and primarily through base 
pairing, engineering the ribozymes to target new transcript regions simply requires 
changing the sequence of the recognition elements to base pair with the desired 
target. Other considerations for ribozyme targeting include reconstituting a u-G 
wobble pair at the 5’ splice site and a guanosine at the 3’ splice site as the last (or 
only) base of the sequence targeted for excision (33). In this report, a single 
nucleotide was targeted for excision, however, previous work with this ribozyme 
demonstrated that segments larger than a single nucleotide can be excised in vitro 
(22, 32). It is anticipated that larger regions could be excised in vivo, and 
investigations into these types of targets would utilize the third recognition element 
(RE2) of the ribozyme. This added interaction could improve the reactivity and 
specificity of the ribozyme in vivo, as it adds to the interactions between the 
ribozyme and its target.  
Comparison to in vitro TES results 
In the simplest TES test system, which involves the excision of a single, 
targeted nucleotide, the ribozyme is able to produce 70% product in vitro under 
optimized conditions of ribozyme excess and 10 mM MgCl2 (22). For the in vivo tests 
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presented here, the ribozyme restores approximately 12% of the fluorescence (30). 
This decrease in reactivity is not unexpected and is likely due to a number of factors. 
Nevertheless, TES ribozymes are adaptable to the cellular environment and are able 
to produce detectable amounts of repaired RNA. 
There are several possible explanations for the difference between the in vitro 
results and the in vivo results. First, the sequences targeted by the ribozymes differ. 
The in vitro system utilizes a substrate that mimics the native exon sequences of the 
P. carinii intron (22), while the in vivo system utilizes a different sequence in the GFP 
gene (30). The differences in the sequences could have an effect on the efficiency of 
the reaction. Target accessibility may also play a role in the levels of correction 
observed. RNA structure prediction models indicated the region containing the 
insertion mutation would be accessible, so it was anticipated that the ribozyme 
would be able to base pair with the target without structural interference. As TES 
correction was observed, the ribozyme was able to recognize the target in vivo. It is 
possible that other factors, such as proteins binding the target transcript, are 
affecting the ability of the ribozyme to effectively recognize its target.  
The differences between the controlled in vitro reaction conditions and the 
cellular environment could also be affecting the structure and the reactivity of the 
ribozyme. The optimum MgCl2 concentration for in vitro TES ribozyme activity for the 
test system excising a single nucleotide is 10 mM (22). The concentration of free 
magnesium in the cell is expected to be much less (137, 138), so other factors may 
be required for the proper folding of the ribozyme. E. coli is a non-native system for 
the P. carinii ribozyme, so species-specific, beneficial cellular cofactors may not be 
available. In vitro, the concentrations of the ribozyme and of the substrate can be 
controlled and the reactions are conducted under ribozyme excess conditions (22, 
32, 33). This level of control is not possible in this in vivo system and the 
concentrations are expected to be closer to a 1:1 ratio. It is possible that cellular 
proteins are binding the ribozyme and are preventing the ribozyme from folding into 
its optimum catalytic conformation. This would also lower the relative concentration 
of active ribozyme. In vitro, guanosine cofactor is not required for the TES reaction. 
As TES reactivity is observed in vivo, it appears that the TES reaction occurs in the 
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presence of free guanosine. The lower levels of TES product formation do not 
appear to be a result of a detrimental effect of transcribing the TES ribozyme in the 
cell, as there was no observed significant difference in growth for cultures containing 
active or inactive ribozymes. 
Another explanation for the lower amount of in vivo TES product formation is 
reduced exon ligation (the product of the second reaction step). Previous work with 
the TES ribozyme in vitro showed that TES product formation could be increased by 
decreasing 3’ exon dissociation after the first reaction step. This dissociation is 
mediated by the presence of sequences downstream of the P10 helix (32). The 
simple substrate (10 nucleotides) used in the in vitro studies (22, 33) does not have 
additional sequences downstream of the P10 helix, while the transcript target in 
these in vivo studies has many nucleotides downstream of the P10 helix (30). The 
presence of these additional sequences could increase the dissociation of the 3’ 
exon. One way to decrease the dissociation is by increasing the length of RE3, 
which increases the length of the P10 helix. A crystal structure of a group I intron 
showed there are no tertiary interactions between the intron and the 3’ exon (109, 
134), so increased base pairing is required to hold the 3’ exon during the reaction. 
Previous in vitro work showed that an RE3 of 5 nucleotides led to a dramatic 
improvement in TES reactivity, while a further increase to 10 nucleotides did not 
improve the reaction over the RE3 of 5 (32). As the greatest increase in GFP 
fluorescence was observed with a ribozyme containing an RE=5 (Figure 4.7), it 
appears that an RE3 of 5 nucleotides may represent an optimum length for reactivity 
in vitro, as well as in vivo. Note RE3 lengths greater than 7 nucleotides were not 
tested in these in vivo studies. The effect of RE3 may not depend solely on length, 
but also on sequence, so longer RE3 lengths may further improve the reaction in 
other systems. 
Comparison to trans-splicing 
The TES ribozyme offers a different approach to RNA repair compared to the 
Tetrahymena-derived trans-splicing ribozyme (7). The trans-splicing ribozyme 
replaces the 3’ exon of a targeted transcript with a new version of the exon carried 
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by the ribozyme. Thus trans-splicing works best for mutations located near the 3’ 
end of the transcript as the ribozyme is required to carry the replacement exon and 
any required regulatory elements contained in the 3’ region of the transcript. The 
TES ribozyme excises an internal segment, so no additional sequences are carried 
by the ribozyme. This lack of extra sequences in the TES ribozyme eliminates 
potential delivery issues that could arise from the size of the repair ribozyme. Also, 
the internal segment targeted for excision by the TES ribozyme can, in theory, be 
located anywhere on the transcript. The excision of an internal segment maintains 
the regulatory elements present in the target transcript, thus eliminating concerns 
about post-transcriptional regulation of the corrected transcript. While the trans-
splicing ribozyme is single turnover, the TES ribozyme has the potential to be a 
multiple-turnover catalyst, as it is not changed in the reaction.  
In E. coli, the level of activity restored by the trans-splicing ribozyme was 
approximately 1% (7). In the study presented here, a higher level of repair in E. coli 
was observed, as the level of activity restored by the TES ribozyme was 
approximately 12% (30). That trans-splicing ribozymes (8, 10, 13, 15, 23, 25, 26, 28, 
29) work fairly well in mammalian cells (upwards of 50%) is encouraging and it is 
anticipated that TES ribozymes will also be active in mammalian systems. As is the 
case with trans-splicing (10, 23, 25, 29), we do not anticipate that TES modification 
will have to be 100% to have measurable effects as a biochemical tool. A low level 
of TES activity may produce a relevant amount of modified transcript for protein 
production. 
Comparison to SMaRT 
RNA transcripts have also been modified by exon replacement using a 
method called spliceosome-mediated RNA trans-splicing, or SMaRT (139, 140). 
SMaRT utilizes a pre-trans-splicing molecule (PTM), which contains the replacement 
exon, and the spliceosomes present in nucleated cells (141). This method aims to 
set up a competition between cis-splicing (occurring between two exons in the same 
transcript) and trans-splicing (occurring between the PTM and one of the exons in 
the target transcript). In terms of RNA repair, SMaRT is more akin to trans-splicing in 
 84 
that it modifies RNA transcripts by replacing a portion of the transcript with a new 
RNA sequence and thus faces some of the same challenges. While the spliceosome 
is a multiple turnover catalyst, the PTM is single turnover since it donates its 
replacement sequence during the reaction. This means SMaRT is not a multiple 
turnover reaction. While SMaRT has been used to replace the 3’ (139, 142, 143) and 
the 5’ (144) ends of mutant transcripts, the splicing event must occur at an 
intron/exon junction. This requirement precludes the use of SMaRT in lower 
organisms. The efficiency of SMaRT is comparable to the repair rates obtained with 
trans-splicing ribozymes (139, 142-145) at the RNA transcript level. SMaRT 
produces measurable amounts of correct protein product, once again indicating that 
100% modification of RNA transcripts is not always necessary to have beneficial 
results.  
Comparison to RNA cleavage methods 
Other approaches that aim to reduce the presence or the effects of mutant 
RNA transcripts in a cell involve cleaving ribozymes, such as the hairpin, 
hammerhead and HDV ribozymes (18, 20, 24, 37, 39, 43, 48, 146, 147); RNA 
interference, or RNAi (24, 36, 39); and antisense oligonucleotides (24, 39, 148). The 
cleaving ribozymes reduce the number of mutant transcripts in a cell by binding a 
target transcript (via base pairing) and cleaving the target in a sequence specific 
manner (24, 39). RNAi utilizes small double-stranded RNA molecules in a RNA-
induced silencing complex (RISC) to identify target transcripts via base pairing. The 
identified targets are then degraded, thus preventing protein synthesis from that 
target (36, 39). Antisense also utilizes small oligonucleotides, but it does not utilize 
the RISC. The base pairing of these antisense RNAs to the target can serve as a 
block to prevent translation, or can mark the transcripts for destruction (24, 39). 
These RNA tools reduce the number of mutant transcripts in a cell and knock out the 
function of the target transcript. TES ribozymes are able to remove defective 
elements of a transcript, without destroying the transcript. Thus, TES ribozymes can 
be used to restore the function to the target transcript. The correction of mutant 
transcripts, as opposed to the destruction of the transcripts, reduces the amount of 
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mutant protein produced while increasing the amount of correct protein being made. 
The TES ribozyme also offers a new approach to mutation analysis. Instead of 
knocking out the function of a gene by destroying the entire target transcript, TES 
ribozymes allow for the removal of specific segments of a transcript, including 
promoters, regulatory elements and binding domains, while maintaining the rest of 
the transcript. Thus, deleterious effects of a mutant transcript can be assigned to 
specific regions of the transcript, which could lead to more directed therapeutic 
approaches.  
Issues 
While the work presented here demonstrates that the TES ribozyme is active 
in E. coli, there are issues that must be overcome to make this ribozyme a generally 
applicable biochemical tool and a potential therapeutic agent. One major obstacle is 
the low level of TES correction. As mentioned above for trans-splicing (10, 23, 25, 
29) and SMaRT (142, 143), TES modification will not necessarily have to be 100% 
to have measurable effects as a biochemical tool. Nevertheless, a higher rate of 
repair is desirable. It should be noted that the ribozyme used in these studies was 
minimally altered from its native state. The possibility of mutating the ribozyme in 
regions other than the recognition elements to improve in vivo activity has not yet 
been investigated. Random mutagenesis of the Tetrahymena group I self-splicing 
intron allowed for selection of introns that were more active in non-native in vivo 
systems (149), so it is anticipated that a similar selection process will allow for the 
selection of TES ribozymes with greater activity in vivo.  
The low levels of TES correction could also be related to poor specificity and 
targeting. These effects are difficult to assess for the TES reaction in vivo. The TES 
ribozyme removes an internal segment from within an RNA and leaves the flanking 
ends intact. The TES ribozyme could be performing only the first step (5’ cleavage) 
on non-targeted transcripts, which would lead to non-productive products. No new 
sequence from the ribozyme is transferred to the targeted transcript, so “tagged” 
transcripts cannot selectively isolated, as was done for trans-splicing, to determine 
optimum reaction sites (12, 17, 19, 23, 26, 29) or to analyze the specificity (8). As no 
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detrimental affect on cell growth from the presence of the active ribozyme was 
observed, it appears that the ribozyme is not attacking crucial transcripts. The 
sequencing results presented in this work showed that the targeted guanosine is 
removed from the fluorescent transcripts, indicating a sequence specific reaction 
(Figure 4.8).  
Targeting is an inherent issue for the TES ribozyme. Internal segments are 
being excised in a sequence specific manner, so one cannot necessarily search for 
accessible sites for targeting. The target choice is determined by the segment 
targeted for removal and its flanking sequences. Thus it is possible that sequences 
that could be targeted for removal in vitro will not be viable targets in vivo due to 
structure or other factors. There may be ways to utilize antisense approaches to 
assess the accessibility of the region of interest at a base pairing level (150), but this 
may not reflect the ability of the ribozyme to bring the target into proper alignment in 
the catalytic core for reactivity. 
Note that the challenges we face in improving the TES reaction in vivo and 
adapting TES ribozymes to a mammalian system are the same challenges faced by 
others developing ribozymes in mammalian systems (24, 39, 151). Common issues 
in E. coli and mammalian cells include increasing the level of ribozyme activity, 
improving ribozyme specificity, assessing target accessibility, and effectively 
delivering the ribozyme. Work is ongoing to address these issues and is 
encouraging (24, 37, 39, 151). Advances in these areas will allow for the further 
development of TES ribozymes as biochemical and therapeutic tools. 
Implications 
The ability of the TES ribozyme to removal internal segments from within 
RNA transcripts offers many potential applications. As biochemical tools, TES 
ribozymes could be used as inducible tools to modulate the production of proteins in 
vivo. As demonstrated in this report, TES ribozymes can be targeted to remove 
sequences to restore the reading frame of a transcript, thus producing active protein. 
The removal of nucleotides to shift the sequence out of frame is also possible, so 
inactive or mutant proteins could also be produced in an inducible manner. 
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The applications of TES ribozymes could also include therapeutic 
applications. Targeting genetic mutations at the DNA level is difficult due to the 
stable structure of DNA. RNA transcripts (which contain the mutations found in the 
DNA sequence) are more accessible and more open to modification. As a 
therapeutic agent, TES ribozymes could be used to remove insertion mutations and 
premature stop codons from transcripts, thus restoring the reading frame of the 
transcript for protein production. We have previously demonstrated the in vitro ability 
of a TES ribozyme to target a small model mimic of the triplet expansion implicated 
in Myotonic Dystrophy and to excise from that mimic a short triplet expansion (22). 
Thus the repair of transcripts involved in triplet expansion diseases, such as 
Muscular Dystrophy and Huntington’s Disease, is another potential application for 
TES ribozymes in vivo. 
Demonstrating TES activity in a cellular context advances the potential uses 
of this ribozyme. As outlined in this work, the TES ribozyme can target a transcript 
and modify it by excising an internal single nucleotide in vivo. The results presented 
here show the potential of the TES ribozyme as a tool for mRNA modification and 
repair. Targeting the GFP gene demonstrates that the recognition elements of the 
ribozyme are mutable in an in vivo setting, as was previously demonstrated in vitro 
(22). The ability to change the recognition elements and to successfully target the 
complement to those recognition elements demonstrates that the TES ribozyme can 
be rationally designed to target and modify transcripts in a sequence specific way in 
vivo. 
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Figure 4.1.  Design of the GFP Target System 
 
Design of the GFP target system (30). The top line shows the sequence of 
interest of the GFP transcript. The designated codon codes for leucine (Codon 201). 
The boxed codons base pair with recognition element 1 (RE1) of the ribozyme. Site-
directed mutagenesis was used alter the GFP coding region to insert a uridine (in 
red) 5’ to a guanosine in the mRNA transcript, which causes a frameshift and a 
premature stop codon (not shown). The TES reaction removes the targeted 
guanosine and restores the correct reading frame of the GFP gene (bottom line). 
Note that the leucine codon is CUU in the corrected transcript, resulting from a G-to-
U transversion from the normal transcript. 
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Figure 4.2.  The Trans Excision-Splicing Ribozyme with a T7 Terminator 
Sequence 
 
The predicted secondary structure of the trans excision-splicing ribozyme 
(rP3X) with the addition of a T7 terminator sequence. The T7 terminator sequence 
(shown in red) stops transcription of the ribozyme in vivo (131).  The above structure 
was adapted from (22). 
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Figure 4.3.  Plasmid Construction 
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Construction of the In Vivo TES Test Plasmid (30). The original TES ribozyme 
plasmid (P3X) was modified by the insertion of a linker containing a T7 terminator 
sequence 3’ to the ribozyme sequence to create P3X + T7T. Site-directed 
mutagenesis was used to create a unique BglII site 5’ to the T7 promoter of the 
ribozyme and a unique SphI site 3’ to the T7 terminator of the ribozyme (P3X + 
T7TBS). The ribozyme construct was isolated from the plasmid by a double 
restriction enzyme digest with BglII and SphI. The GFP-containing plasmid, pQBI 
T7-GFP (QBIOGENE), was prepared for insertion of the ribozyme construct by a 
double restriction enzyme digest with BglII and SphI. The ribozyme construct was 
ligated into the cut pQBI T7-GFP plasmid to create pQBI GFP + P3X. Modifications 
to the GFP gene to create the mutant and corrected forms and modifications to the 
ribozyme to change the recognition elements and to create the inactive forms were 
all created via site-directed mutagenesis. 
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 Figure 4.4.  GFP Ribozyme Base Pairing With Its Target 
 
The GFP rP3X ribozyme is in uppercase lettering, the GFP target is in 
lowercase lettering, the insertion mutation (uridine) is in red, and the guanosine to be 
excised (ωG) is encircled. The ribozyme recognition elements RE1, RE2, and RE3 
base pair with the substrate to form the P1, P9.0, and P10 helices, respectively. 
Note that the P9.0 helix is not formed in this system. The sites of catalysis for the 
first step (5’ cleavage) and the second step (exon ligation) are shown with large bold 
arrows. The 3-base P10 helix is boxed, with brackets indicating the extensions to 5 
and 7 bases. Note that the diagram only shows the recognition elements of the 
ribozyme. This ribozyme is the same as rP-8/4x (11), except for the sequences of 
RE1 and RE3 and the addition of a T7 terminator (131) on the 3’ end (Figure 4.2). 
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Figure 4.5.  Schematic of the Assay to Selectively Isolate Corrected 
Transcripts 
 
Schematic of the assay developed to selectively isolate corrected GFP 
transcripts (30). Total RNA is isolated from cells that have undergone in vivo testing. 
RT-PCR is used to amplify the GFP coding region from the isolated RNA. The 
resulting RT-PCR products are ligated into the pDrive PCR cloning vector (Qiagen). 
Note that the RT-PCR products can be ligated into the vector in the forward direction 
(which puts the GFP gene in frame with the LacZ α-peptide of the plasmid) or the 
reverse direction, with each direction assumed to be equally possible. Only products 
ligated in the forward direction will product fluorescent GFP. The colonies resulting 
from transformation of the ligated plasmids into E. coli cells are exposed to UV light 
to identify fluorescent colonies. Selected colonies are grown up in bulk culture. The 
resulting plasmids are isolated and sequenced to confirm the expected sequence 
change in the corrected transcripts. 
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Figure 4.6.  Fluorescence Levels for Normal, Mutant and Expected Product 
Forms of GFP 
 
Comparison of the normalized GFP fluorescence levels for the normal, 
mutant and expected product forms of GFP in the presence of active, non-targeted 
ribozyme (30). All points utilize constructs with the non-targeted ribozyme (rP3X) 
and the GFP form listed on the graph. Normalized fluorescence was determined by 
correcting the raw fluorescence for differences in cell density (determined by the 
absorbance of the bulk culture at 600nm) and normalizing to non-induced controls. 
Each data point represents 4 independent assays and the standard deviations are 
below 10%. 
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Figure 4.7.  TES Correction of Mutant GFP 
 
Normalized fluorescence data for constructs pairing mutant GFP with the TES 
ribozymes (30). All points utilize the mutant GFP target with the ribozyme listed 
above the graph. The green bars (+) indicate active ribozymes, while the black bars 
(–) indicate the ribozymes have been inactivated by a deletion in the guanosine 
binding site. Normalized fluorescence was determined by correcting the raw 
fluorescence for differences in cell density (determined by the absorbance of the 
bulk culture at 600nm) and normalizing to non-induced controls. Each data point 
represents 4 independent assays and the standard deviations are below 10%. 
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Figure 4.8.  Sequencing Results for Non-Fluorescent and Fluorescent Colonies 
 
Sequencing confirmation of the in vivo TES reaction (30). Sequencing results 
for uncorrected GFP (left) and corrected GFP (right) transcripts. Total RNA isolated 
from in vivo tests involving the construct Mut GFP + GFP rP3X RE3=5 was utilized 
as the template for RT-PCR to isolate GFP transcripts. The uncorrected GFP 
sequence represents plasmids isolated from non-fluorescent colonies. The corrected 
GFP sequence represents plasmids isolated from fluorescent colonies. 
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CHAPTER 5 - CONCLUSIONS 
 
The trans excision-splicing reaction is a potentially useful biochemical tool for 
the sequence specific modification of RNAs. While the ability of the Pneumocystis 
carinii ribozyme to catalyze this reaction using small RNA substrates in vitro had 
been demonstrated previously (22, 32), many questions remain about the 
interactions between the ribozyme and its target, as well as about the abilities of this 
ribozyme in a cellular setting. The work presented in this dissertation further 
characterizes the P. carinii ribozyme in vitro and gives insight into the molecular 
recognition of the 5’ and 3’ splice sites by this ribozyme. These studies also 
demonstrate, for the first time, that this ribozyme-catalyzed reaction can occur in 
vivo. 
The Sequence Requirements for the TES Ribozyme at the 5’ and 3’ Splice Sites 
The work investigating the sequence requirements of the trans excision-
splicing ribozyme at the 5’ and 3’ splice sites has provided further insight into the 
molecular recognition of this ribozyme. The sequence requirements at the 5’ splice 
site are not stringent, as all base pair combinations allow some level of 5’ cleavage 
(the first reaction step). Sequences other than the highly conserved u-G wobble pair 
can produce TES product in appreciable yields. The greatest TES product yields 
required a stable base pair (a Watson-Crick or wobble pair) at the 5’ splice site, 
indicating stricter sequence requirements for the second reaction step (exon 
ligation). The degradation of TES products containing Watson-Crick base pairs at 
the 5’ splice site demonstrated that the ribozyme recognizes a structural perturbation 
in the helix formed between the recognition elements of the ribozyme and the 
substrate. Non-Watson-Crick base pairs and ωG can play a role in 5’ splice site 
determination by creating this perturbation. This structural perturbation had not been 
demonstrated previously and these results are the first to implicate ωG in 5’ splice 
site determination (33). This role of ωG may be limited to these simple target 
systems where a single nucleotide is removed due to its location immediately 
adjacent to the 5’ cleavage site. 
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The sequence requirements at the 3’ splice site are absolute, with only 
guanosine in the ω position allowing TES product formation. The specificity of the 
ribozyme for ωG is determined by the G-binding site of the ribozyme. Attempts to 
rationally redesign this site to accept a different nucleotide were unsuccessful, so in 
its current state, the TES ribozyme is only able to remove single guanosine 
insertions or sequences ending in guanosine from RNA substrates.  
The results of this study gave us insight into the molecular recognition of the 
splice sites by this ribozyme. We are able to develop guidelines for new TES target 
systems, particularly in terms of the 5’ splice site. The highly conserved u-G wobble 
pair can be replaced with other base pairs, which expands the pool of potential 
substrates for TES reactions. The results obtained from the studies presented here 
give an indication of sequence combinations that will provide the most specific 
ribozyme for a particular target.  
The TES Ribozyme Can Excise a Single, Targeted Nucleotide from an mRNA In 
Vivo 
The studies outlined in this work demonstrate that the TES ribozyme is active 
in a cellular setting. The ribozyme was successfully reengineered to excise a single, 
targeted nucleotide from within an RNA transcript in E. coli. The transcription of 
active ribozyme produced no observed negative effect on cell growth, indicating that 
production of the ribozyme was not detrimental to the cell. The ribozyme was able to 
correct the mutant, targeted transcripts, resulting in a measurable restoration of 
protein activity. The ribozyme catalyzes the successful TES reaction in a sequence 
specific manner, as the sequenced corrected transcripts showed the targeted 
guanosine had been removed.  
These results begin the characterization of the TES ribozyme in the cellular 
environment. For the first time, we have demonstrated that the ribozyme is able to 
target and remove a sequence from within an RNA transcript. An RNA transcript is 
more complex than the small RNA substrates utilized in the previous in vitro studies, 
as there are other sites that the ribozyme could potentially base pair with. RNA 
transcripts could also contain structure that would interfere with ribozyme binding. 
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The ribozyme was able to overcome these potential issues and successfully excised 
the targeted nucleotide from GFP transcripts.  
These results are also the first demonstration of a catalytic RNA sequence 
specifically removing a targeted segment from within an mRNA in vivo. This targeted 
segment can be as small as a single nucleotide. The demonstration of this in vivo 
reactivity paves the way for the future development of this ribozyme-catalyzed 
reaction as a biochemical tool and as a potential therapeutic. 
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